Acute Myeloid Leukemia
About the NCCN Guidelines for Patients®

Did you know that top cancer centers across the United States work together to improve cancer care? This alliance of leading cancer centers is called the National Comprehensive Cancer Network® (NCCN®).

Cancer care is always changing. NCCN develops evidence-based cancer care recommendations used by health care providers worldwide. These frequently updated recommendations are the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). The NCCN Guidelines for Patients plainly explain these expert recommendations for people with cancer and caregivers.

These NCCN Guidelines for Patients are based on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia, Version 1.2023 – March 3, 2023.

View the NCCN Guidelines for Patients free online NCCN.org/patientguidelines

Find an NCCN Cancer Center near you NCCN.org/cancercenters

Connect with us  Facebook  Twitter  Instagram  YouTube  LinkedIn
Supporters

NCCN Guidelines for Patients are supported by funding from the NCCN Foundation®

NCCN Foundation gratefully acknowledges the following corporate supporters for helping to make available these NCCN Guidelines for Patients: AbbVie and Astellas.

NCCN independently adapts, updates, and hosts the NCCN Guidelines for Patients. Our corporate supporters do not participate in the development of the NCCN Guidelines for Patients and are not responsible for the content and recommendations contained therein.

To make a gift or learn more visit online or email

NCCNFoundation.org/donate  PatientGuidelines@NCCN.org
Contents

4 AML basics
8 Testing for AML
22 Treating AML
35 AML
48 APL
55 BPDCN
61 Making treatment decisions
74 Words to know
78 NCCN Contributors
79 NCCN Cancer Centers
80 Index
1

AML basics

5 Blood
7 Acute myeloid leukemia
7 Key points
Acute myeloid leukemia (AML) is a type of blood cancer that starts in the blood stem cells of bone marrow. There are many types of AML found in adults. This chapter will provide an overview of AML.

Blood

Acute myeloid leukemia (AML) is a type of blood cancer. Blood is a tissue. A tissue is a group of cells that work together to perform a function. Blood’s function is to move oxygen and nutrients throughout the body and carry away waste. Blood also plays an important role for the immune system and in preventing bleeding.

Blood cells

Your blood contains different types of cells that float in plasma. Plasma is a clear, yellowish fluid made up of mostly water. More than half of your blood is plasma.

There are 3 types of blood cells:

- Red blood cells (erythrocytes)
- White blood cells (leukocytes), which include granulocytes, monocytes, lymphocytes, and others
- Platelets (thrombocytes)

Blood cells have important jobs. Red blood cells (RBCs) carry oxygen throughout the body. White blood cells (WBCs) fight infections. Platelets (PLTs) help control bleeding. Blood cells are being replaced in your body all the time. Many have a short lifespan. Some white blood cells live less than one day. Your body makes one million red blood cells every second!
How blood cells are formed

Bone marrow is the sponge-like tissue in the center of most bones. Inside your bone marrow are early blood-forming cells called blood stem (hematopoietic) cells. All types of blood cells are created from blood stem cells. At any given time, bone marrow will have cells in various stages of development, from very immature to almost fully mature. This process is called differentiation. After a blood stem cell develops into a red blood cell, white blood cell, or platelet, it is released in your bloodstream as needed.

Blood stem cells can copy themselves or “self-renew.” These cells are rare. The role of blood stem cells is to make cells that will become red blood cells, white blood cells, and platelets. These are called progenitor cells or precursor cells.

There are different types of progenitor cells:

- **Lymphoid progenitor cells** form into lymphoblasts that mature into lymphocytes
- **Myeloid progenitor cells** form into myeloblasts and other non-lymphoid blood cells.

AML starts in myeloid progenitor cells causing abnormal myeloblasts (blasts).

---

**Blood cell formation**

All blood cells start as blood stem cells. A blood stem cell has to mature or go through many stages to become a red blood cell, white blood cell, or platelet. AML affects the myeloid progenitor cells, which develop into red blood cells, granulocytes (a type of white blood cell), and platelets.

Blasts

A blast is an immature white blood cell. Both lymphoid and myeloid progenitor cells form into blast cells called lymphoblasts or myeloblasts depending on the type. Blasts are committed to becoming a type of blood cell. Lymphoblasts normally mature into lymphocytes, a type of white blood cell. Myeloblasts are responsible for all other non-lymphoid blood cells in bone marrow, such as granulocytes, another type of white blood cell.

Acute myeloid leukemia

Acute myeloid leukemia (AML) is a cancer of myeloid progenitor cells. Changes in these cells stop myeloid blasts (or myeloblasts) from becoming mature blood cells. As a result, there is a buildup of blasts in the marrow and blood. In turn, there are not enough healthy red blood cells, platelets, and white blood cells. This causes serious health issues. For this reason, AML is fatal if left untreated.

Traditionally, to be diagnosed with AML, 20 percent (20%) or more myeloid blasts must be present in the marrow or blood. This means that at least 1 out of every 5 marrow cells are blasts. In certain cases, myelodysplastic syndromes (MDS) can also have increased blasts. As a result, MDS with 10% to 19% blasts is called MDS/AML. In certain cases, a diagnosis of AML is possible with any number of blasts, particularly if certain molecular alterations are also present.

Types of AML

There are many types of AML. They are grouped and treated based on the presence or absence of certain gene mutations and other factors.

Treatment chapters in this book are divided into:

- Acute myeloid leukemia (AML)
- Acute promyelocytic leukemia (APL)
- Blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Key points

- AML is a blood cancer of the myeloid progenitor cells. Changes in these cells stop myeloid blasts from becoming mature blood cells. As a result, there is a buildup of blasts in the marrow and blood making it hard for blood to do its work.
- Traditionally, to be diagnosed with AML, 20 percent (20%) or more myeloid blasts must be present in the marrow or blood. This means that at least 1 out of every 5 marrow cells are blasts. In certain cases, a diagnosis of AML is possible with any number of blasts, particularly if certain molecular alterations are also present.
- There are many subtypes of AML. They are grouped and treated based on gene mutations and other factors.
2

Testing for AML

9  Test results  
10 General health tests  
11 Blood tests  
14 Performance status  
14 Tissue tests  
16 Genetic and biomarker testing  
18 Imaging tests  
19 Heart tests  
20 Lumbar puncture  
21 Key points
Accurate testing is needed to diagnose and treat acute myeloid leukemia (AML). This chapter presents an overview of possible tests and what to expect.

## Test results

Accurate testing is needed to diagnose and treat AML. A diagnosis of AML is based on the presence of myeloid blasts in the marrow or blood. The number of blasts required to be diagnosed with AML can vary. Traditionally, the number of blasts must be 20 percent (20%) or more. This means that at least 1 out of every 5 marrow cells are blasts. If there are fewer blasts, then a common biomarker must be present.

Results from blood tests, bone marrow aspirate and biopsy, and imaging studies will be used to determine your treatment plan. It is important you understand what these tests mean. Ask questions and keep copies of your test results. Online patient portals are a great way to access your test results.

Keep these things in mind:

- Choose a friend, family member, or peer who can drive you to appointments, provide meals, or offer emotional support during diagnosis and treatment.
- Bring someone with you to doctor visits, if possible.
- Write down questions and take notes during appointments. Don’t be afraid to ask your care team questions. Get to know your care team and help them get to know you.
- Get copies of blood tests, imaging results, and reports about the specific type of cancer you have.
- Organize your papers. Create files for insurance forms, medical records, and test results. You can do the same on your computer.
- Keep a list of contact information for everyone on your care team. Add it to your phone. Hang the list on your refrigerator or keep it in a place where someone can access it in an emergency. Keep your primary care physician (PCP) informed of changes to this list. You are encouraged to keep your PCP. They are great partners in your care.
- Include in your contact list information on the exact type of cancer, as well as any treatment and the date it started.

Those with AML should be treated at experienced leukemia centers.
General health tests

Medical history

A medical history is a record of all health issues and treatments you have had in your life. Be prepared to list any illness or injury and when it happened. Bring a list of old and new medicines and any over-the-counter (OTC) medicines, herbals, or supplements you take. Some supplements interact and affect medicines that your care team may prescribe. Tell your care team about any symptoms you have. A medical history, sometimes called a health history, will help determine which treatment is best for you.

Physical exam

During a physical exam, your health care provider may:

- Check your temperature, blood pressure, pulse, and breathing rate
- Check your height and weight
- Listen to your lungs and heart
- Look in your eyes, ears, nose, and throat
- Feel and apply pressure to parts of your body to see if organs are of normal size, are soft or hard, or cause pain when touched.
- Feel for enlarged lymph nodes in your neck, underarm, and groin.

Guide 1

Possible tests and procedures: AML

<table>
<thead>
<tr>
<th>Test Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical history and physical exam (H&amp;P)</td>
</tr>
<tr>
<td>Complete blood count (CBC), platelets, differential, comprehensive metabolic panel (CMP), uric acid, lactate dehydrogenase (LDH), B12, and folic acid</td>
</tr>
<tr>
<td>Blood clotting tests</td>
</tr>
<tr>
<td>Bone marrow aspirate and biopsy with biomarker and genetic testing</td>
</tr>
<tr>
<td>Human leukocyte antigen (HLA) typing</td>
</tr>
<tr>
<td>Brain CT without contrast, if central nervous system (CNS) bleed suspected</td>
</tr>
<tr>
<td>Brain MRI with contrast, if leukemic meningitis suspected</td>
</tr>
<tr>
<td>PET/CT, if leukemia outside the blood and bone marrow (extramedullary) suspected</td>
</tr>
<tr>
<td>Lumbar puncture (LP)</td>
</tr>
<tr>
<td>Heart tests</td>
</tr>
</tbody>
</table>
Family history

Some cancers and other diseases can run in families. Your doctor will ask about the health history of family members who are blood relatives. This information is called a family history. Ask family members on both sides of your family about their health issues like heart disease, cancer, and diabetes, and at what age they were diagnosed. It’s important to know the specific type of cancer, or where the cancer started, and if it is in multiple locations. Those with a family history of leukemia, blood cancer or abnormalities, or certain genetic mutations might be referred to genetic counseling.

Blood tests

Blood tests check for signs of disease and how well organs are working. They require a sample of your blood, which is removed through a needle placed into a vein. Be prepared to have many blood tests during AML treatment and recovery to check treatment results, blood counts, and the health of organs like your liver and kidneys.

Tests described next are listed alphabetically and not in order of importance.

B12 and folic acid

Vitamin B12 and folic acid (folate) work with vitamin C to help the body make new proteins. They are needed for normal red blood cell (RBC) and white blood cell (WBC) formation. B12 and folic acid levels will be monitored. You may be given vitamin supplements, if needed.

Blood clotting tests

Your body stops bleeding by turning blood into a gel-like form. The gel-like blood forms into a solid mass called a blood clot. Clotting is a process or series of events. Proteins, called coagulation factors, are needed for clotting. They are made by the liver. These tests are known together as a coagulation panel or disseminated intravascular coagulation (DIC) panel.

It is standard to screen for clotting problems. An impaired clotting process is common in leukemia. This is called coagulopathy. You may have bleeding and bruises.

Blood urea nitrogen

Blood urea nitrogen (BUN) is a waste product filtered out of the blood by the kidneys. A high level of BUN can be a sign your kidneys aren’t working well.

Comprehensive metabolic panel

A comprehensive metabolic panel (CMP) is a test that measures 14 different substances in your blood. It is usually done on the plasma part of your blood. A CMP provides important information about how well your kidneys and liver are working, among other things.

Complete blood count and differential

A complete blood count (CBC) measures the levels of red blood cells (RBCs), white blood cells (WBCs), and platelets (PLTs) in your blood. A CBC is a key test that gives a picture of your overall health. AML often causes low counts of healthy blood cells, but it can also present with a high number of abnormal, malignant (abnormal) white blood cells.
Testing for AML  » Blood tests

There are several types of white blood cells. A differential counts the number of each type of white blood cell. It also checks if the counts are in balance with each other. This test may show a high number of blasts in the blood.

**Creatinine**
Creatinine is a waste produced in the muscles. Every person generates a fixed amount of creatinine every day based on how much muscle they have. It is filtered out of the blood by the kidneys. The level of creatinine in the blood tells how well the kidneys are working. Higher levels of creatinine mean the kidneys aren't working as well as they were when someone had lower levels of creatinine.

**Electrolytes**
Electrolytes help move nutrients into cells and help move waste out of cells. Electrolytes are ions or particles with electrical charges that help the nerves, muscles, heart, and brain work as they should. Your body needs electrolytes to function properly. Phosphate (PO4) is important for strong bones and teeth. Too much phosphate in blood can be a sign your kidneys aren't working well.

**Iron**
Iron is important in maintaining body functions such as producing hemoglobin, the molecule in your blood that carries oxygen. You might be monitored for low levels of iron called iron deficiency. You may be given intravenous (IV) iron supplement, if needed. It is possible to have too much iron in the body called overload. Therefore, only take what is prescribed by your doctor.

---

Create a medical binder

A medical binder or notebook is a great way to organize all of your records in one place.

- Make copies of blood tests, imaging results, and reports about your specific type of cancer. It will be helpful when getting a second opinion.
- Choose a binder that meets your needs. Consider a zipper pocket to include a pen, small calendar, and insurance cards.
- Create folders for insurance forms, test types (ie, blood, imaging, pathology, radiology, genetics), treatments, and procedures. Organize items in the folder by date.
- Use online patient portals to view your test results and other records. Download or print the records to add to your binder.
- Add a section for questions and to take notes.

Bring your medical binder to appointments. You never know when you might need it!
Lactate dehydrogenase

Lactate dehydrogenase (LDH) or lactic acid dehydrogenase is a protein found in most cells. Dying cells release LDH into blood. Fast-growing cells also release LDH. High levels of LDH can be a sign of AML.

Liver function tests

Liver function tests (LFTs) look at the health of your liver by measuring chemicals that are made or processed by the liver. Levels that are too high or low signal that the liver is not working well.

Phosphate

Cells have a lot of phosphate in them. Therefore, when many cells are breaking down at the same time, the levels of phosphate in the blood can go up. Your kidneys help get rid of extra phosphate, but too much phosphate in the blood can also damage the kidneys, making it harder to get the levels back down to normal.

Uric acid

Uric acid is released by cells when DNA breaks down. It is a normal waste product that dissolves in your blood and is filtered by the kidneys where it leaves the body as urine. Too much uric acid in the body is called hyperuricemia. With AML, it can be caused by a fast turnover of white blood cells. High uric acid might be a side effect of chemotherapy or radiation therapy. Very high levels of uric acid in the blood can damage the kidneys.

HLA typing

A human leukocyte antigen (HLA) is a protein found on the surface of most cells. It plays an important role in your body’s immune response. HLAs are unique to each person. They mark your body’s cells. Your body detects these markers to tell which cells are yours. In other words, all your cells have the same set of HLAs. Each person’s set of HLAs is called the HLA type or tissue type.

HLA typing is a test that detects a person’s HLA type. This test is done before a donor (allogeneic) blood stem cell transplant, also called a hematopoietic cell transplant (HCT). To find a donor match, your proteins will be compared to the donor’s white blood cells to see how many proteins are the same. A very good match is needed for a transplant to be a treatment option. Otherwise, your body will reject the donor cells or the donor cells will react against your body. Blood samples from you and your blood relatives will be tested first.
Performance status

Performance status (PS) is a person’s general level of fitness and ability to perform daily tasks. Your state of general health will be rated using a PS scale called Eastern Cooperative Oncology Group (ECOG). PS is one factor taken into consideration when choosing a treatment plan. Your preferences about treatment are always important.

The ECOG PS scores range from 0 to 5.

- **PS 0** means the person is fully active.
- **PS 1** means the person is still able to perform light to moderate activity, but with some limitations.
- **PS 2** means the person is limited to the chair or bed less than half of the time and still able to care for self.
- **PS 3** means the person is limited to the chair or bed more than half of the time.
- **PS 4** means the person is totally confined to the bed or chair and completely unable to care for self.
- **PS 5** means the person is not alive.

Good PS is usually PS 0 or PS 1.

Tissue tests

An aspirate or a biopsy is the removal of a sample of tissue or group of cells for testing. A diagnosis of AML is confirmed using a bone marrow aspirate and bone marrow biopsy.

Bone marrow tests

Leukemia starts in the bone marrow. To diagnose AML samples of bone marrow must be removed and tested before starting any treatment. Your sample should be reviewed by a pathologist who is an expert in the diagnosis of AML. This review is often referred to as histology, histopathology, or hematopathology review. The pathologist will note the overall appearance and the size, shape, and type of your cells.

If the blastic plasmacytoid dendritic cell neoplasm (BPDCN) subtype of AML is suspected, you might have a lymph node biopsy or a skin lesion biopsy. This would be in addition to the standard bone marrow tests described next.

There are 2 types of bone marrow tests that are often done at the same time:

- Bone marrow aspirate
- Bone marrow biopsy

Your bone marrow is like a sponge holding liquid and cells. An aspirate takes some of the liquid and cells out of the sponge, and a biopsy takes a piece of the sponge.

For many, this is a painful procedure. Your care team will try to make you as comfortable as possible. The samples are usually taken from the back of the hip bone (pelvis). You will likely lie on your belly or side. For an aspirate, a hollow needle will be pushed through your skin and into the bone. Liquid bone marrow will
then be drawn into a syringe. For the biopsy, a wider needle will be used to remove a core sample. You may feel bone pain at your hip for a few days. Your skin may bruise.

**Flow cytometry**

Flow cytometry is a laboratory method used to detect, identify, and count specific cells. Flow cytometry involves adding a light-sensitive dye to cells. The dyed cells are passed through a beam of light in a machine. The machine measures the number of cells, things like the size and shape of the cells, and other unique features of cells.

A complete blood test can count the number of white blood cells, but it cannot detect the subtle differences between different types of blood cancers. Flow cytometry can detect these subtle differences. The most common use of flow cytometry is in the identification of markers on cells, particularly in the immune system (called immunophenotyping).

**Immunophenotyping**

Immunophenotyping uses antibodies to detect the presence or absence of white blood cell antigens called biomarkers. These antigens are proteins that can be found on the surface of or inside white blood cells. Certain biomarkers are targeted in AML treatment.

**Immunohistochemistry**

Immunohistochemistry (IHC) is a special staining process that involves adding a chemical marker to cells. The cells are then studied using a microscope.

---

**Bone marrow aspirate and biopsy**

Samples of bone and marrow are removed in a biopsy.
Testing for AML  » Genetic and biomarker testing

Genetic and biomarker testing

Genetic and biomarker tests are used to learn more about your type of AML, to target treatment, and to determine the likely path your cancer will take (prognosis). This genetic testing is different from family history genetic testing. AML genetic testing looks for changes only in the leukemia cells that have developed over time, and not changes in the rest of your body’s cells. Biomarker testing includes tests of genes or their products (proteins) and identifies the presence or absence of mutations and certain proteins. It is sometimes called molecular testing, tumor profiling, gene expression profiling, or genomic testing.

Inside our cells are deoxyribonucleic acid (DNA) molecules. These molecules are tightly packaged into what is called a chromosome. Chromosomes contain most of the genetic information in a cell. Normal human cells contain 23 pairs of chromosomes for a total of 46 chromosomes. Each chromosome contains thousands of genes. Genes are coded instructions for the proteins your cells make. Most genes contain information about a specific protein. A mutation is when something goes wrong in the genetic code. Proteins are written like this: PML. Genes are written in italics like this: \textit{PML}.

AML cells sometimes have changes in genes and chromosomes that can be seen under a microscope or found with other tests.

Mutations

AML cells can have changes in genes and chromosomes. Mutation testing looks for these changes or abnormalities that are unique to AML cells. Examples of such changes are called deletion, insertion, amplification, translocation (rearrangement), and point mutation.

- **Amplification** – When a part or whole chromosome or gene is increased (for example, duplicated)
- **Deletion** – When part of a chromosome or gene is missing such as del(5q)
- **Insertion** – When a new part of a chromosome or gene is included
- **Inversion** – Switching of parts within one chromosome such as inv(16) and inv(3)
- **Point mutation** – When part of a gene is changed
- **Chromosome translocation and gene rearrangement** – Switching of parts between 2 chromosomes. When described at the chromosome level, it is called a translocation. When described at the gene level, it is called rearrangement. For example, the chromosome translocation is written as t(8;21)(q22;q22.1) and its gene rearrangement is written as \textit{RUNX1}::\textit{RUNX1T1}.
Leukemia predisposition syndromes

Some hereditary cancer syndromes can be passed down from biological parent to child. A family history of leukemia can affect treatment. A skin punch biopsy might be done if a predisposition condition is suspected. If your blood was tested at diagnosis, you would see the genetic changes of the leukemia. Therefore, a skin punch biopsy is used. In this procedure, a small piece of skin and connective tissue is removed to get DNA that hasn’t been altered by AML. This will be used to see if you inherited genes that increase your risk of leukemia. Leukemia predisposition syndrome can affect how your body responds to treatment. Blood and saliva can be used when AML cells disappear (in remission). Biological family members who are possible hematopoietic stem cell donors might be tested for leukemia predisposition syndrome.

While it can be confusing, just know that testing done to look for an inherited gene (germline) mutation or an inherited risk of cancer is different than genetic testing done specifically on cancer cells or testing to look for proteins produced by cancer cells.

AML mutation testing

A sample of your blood or bone marrow will be studied to see if the AML cancer cells have any specific mutations. This is separate from the genetic testing for mutations that you may have inherited from your biological parents.

AML cells can have changes in genes and chromosomes. Mutation testing using methods such as karyotype, FISH, PCR, and next-generation sequencing (NGS) are used to look for these changes or abnormalities. Some mutations may determine the type of treatment given.

Karyotype

A karyotype is a picture of chromosomes. Normal human cells contain 23 pairs of chromosomes for a total of 46 chromosomes. A karyotype will show extra, missing (deletion), translocated, or abnormal pieces of chromosomes within the leukemia cells. Since a karyotype requires growing cells, a sample of bone marrow or blood must be used.

FISH

Fluorescence in situ hybridization (FISH) is a method that involves special dyes called probes that attach to pieces of DNA. FISH can look for mutations that are too small to be seen with other methods. It can only be used for known changes. Since this test doesn’t need growing cells, it can be performed on either a bone marrow or blood sample. Sometimes, a bone marrow sample is needed to get all the information the care team needs to help plan your treatment.

PCR

A polymerase chain reaction (PCR) is a lab process that can make millions or billions of copies of one’s DNA or RNA (genetic information). PCR is very sensitive. It can find 1 abnormal cell among more than 100,000 normal cells. These copies, called PCR product, might be used for NGS. This is important when testing for treatment response or remission. A real-time or reverse transcriptase (RT) is a type of PCR used to look for gene rearrangements such as PML::RARA.
Next-generation sequencing

Next-generation sequencing (NGS) is a method used to determine a portion of a person’s DNA sequence. It shows if a gene has any mutations that might affect how the gene works. NGS looks at the gene in a more detailed way than other methods, and can find mutations that other methods might miss.

Imaging tests

Imaging tests take pictures of the inside of one’s body to look for sites with leukemia. Leukemia can spread outside the bloodstream to lymph nodes, liver, spleen, and skin. It rarely spreads to the lining of the brain and spinal cord. Imaging tests can also show areas of infection or bleeding that may impact your care.

A radiologist, an expert in interpreting imaging tests, will write a report and send this report to your doctor. The doctor will discuss the results with you. While these reports are available to you through your portal, please wait to discuss these results with the doctor.

Contrast material

Contrast material is used to improve the pictures of the inside of the body. Contrast materials are not dyes, but substances that help enhance and improve the images of several organs and structures in the body. It is used to make the pictures clearer. Contrast might be taken by mouth (oral) or given through a vein (IV). The contrast is not permanent and will leave the body in one’s urine after the test. The types of contrast vary and are different for CT and MRI.

Tell your care team if you have had allergic reactions to contrast in the past, especially to iodine, or if you have an allergy to shellfish like shrimp. This is important. You might be given medicines to avoid the effects of those allergies. Contrast might not be used if you have a serious allergy or if your kidneys aren’t working well.

Brain CT

A computed tomography (CT or CAT) scan uses x-rays and computer technology to take pictures of the same body part from different angles. All the images are combined to make one detailed three-dimensional (3D) picture. A CT of the brain is used to look for bleeding. Contrast should not be used.

Brain MRI

A magnetic resonance imaging (MRI) scan uses radio waves and powerful magnets to take pictures of the inside of the body. It does not use x-rays. A device will be placed around your head that sends and receives radio waves. An MRI can show if the outer layer of the brain is swollen. Swelling caused by leukemia is called leukemic meningitis. Contrast should be used.

A closed MRI has a capsule-like design where the magnet surrounds you. An open MRI has a magnetic top and bottom, which allows for an opening on each end. Closed MRIs are more common than open MRIs, so if you have claustrophobia (a dread or fear of enclosed spaces), be sure to talk to your care team about it. Also, tell your doctor if there is any metal in your body.

PET scan

A positron emission tomography (PET) scan uses a radioactive drug called a tracer. A tracer is a substance injected into a vein to
see where cancer cells are in the body and if they are using sugar produced by your body to grow. Cancer cells show up as bright spots on PET scans because they use sugar more quickly than other cells. However, not all cancer cells will appear on a PET scan. Also, not all bright spots are cancer. It is normal for the brain, heart, kidneys, and bladder to be bright on PET. Inflammation or infection can also show up as a bright spot. When a PET scan is combined with CT, it is called a PET-CT scan. It may be done with one or two machines depending on the cancer center. A PET scan is not used very often in AML.

Heart tests

Heart or cardiac tests are used to see how well your heart works. These tests might be used to monitor treatment side effects. You might be referred to a cardiologist.

Electrocardiogram

An electrocardiogram (ECG or EKG) shows electrical changes in your heart. It reveals information about your heart rate and rhythm. Prolonged corrected QT interval (or QTc) occurs when your heart muscle takes longer than normal to recharge between beats. Often, this electrical disturbance can be seen on an ECG. Certain treatments for AML can cause prolonged QTc. If the QTc becomes too prolonged, it can cause dangerous heart rhythms.

Echocardiogram

An echocardiogram (or echo) uses sound waves to make pictures. For this test, small patches will be placed on your chest to track your heartbeat. Next, a wand (called a transducer) with gel on its tip will be slid across part of your bare chest. A picture of your beating heart will be seen on a screen. The pictures will be recorded for future viewing.

MUGA

A multigated acquisition (MUGA) scan is used to evaluate the pumping function of your heart. During the test, a small amount of radiotracer will be injected into a vein. A special camera, called a gamma camera, will create computer-generated movie images of your beating heart.

A MUGA scan might show low ejection fraction. This is when the amount of blood pumping from the left side of the heart is lower than normal.
Lumbar puncture

Leukemia can travel to the fluid that surrounds the spine or brain. This may cause symptoms. In order to know if leukemia cells are in your spinal fluid, a sample must be taken and tested to rule out a central nervous system (CNS) disease.

A lumbar puncture (LP) is a procedure that removes spinal fluid. It is also called a spinal tap. A lumbar puncture may also be used to inject cancer drugs into spinal fluid. This is called intrathecal (IT) chemotherapy.

During a spinal tap, you will be lying down or sitting on an exam table. If lying down, your knees must be tucked up near your chest. If sitting, you must lean forward toward your knees. The lower part of your back over your spine will be numbed. Next, a thin needle will be inserted between your spinal bones. You may feel some pressure. After the sample is taken, it will be sent to a lab for testing.
Key points

- Results from blood tests, bone marrow aspirate and biopsy, and imaging studies will determine your treatment plan.

- An aspirate or biopsy is the removal of a sample of tissue or group of cells for testing. A diagnosis of AML is confirmed using a bone marrow aspirate and bone marrow biopsy.

- Genetic tests are used to learn more about your type of AML, to target treatment, and to determine the likely path your cancer will take (prognosis).

- Biomarker testing includes tests of genes or their products (proteins). It identifies the presence or absence of mutations and certain proteins that might suggest treatment and prognosis.

- HLA typing should be done in those with newly diagnosed AML for whom allogeneic (donor) hematopoietic cell transplant (HCT) is an option.

- Imaging tests are used to look for sites of infection, bleeding, and leukemia that might have spread outside the bloodstream.

- Heart or cardiac tests might be needed to test how well your heart works.

- A lumbar puncture (LP) may be done to look for leukemia in spinal and brain fluid.

- Online patient portals are a great way to access your test results.

Let us know what you think!

Please take a moment to complete an online survey about the NCCN Guidelines for Patients.

NCCN.org/patients/response
3

Treating AML

23 Care team
24 Systemic therapy
25 Chemotherapy
27 Targeted therapy
28 Clinical trials
30 Hematopoietic cell transplant
31 Steroids
31 Radiation therapy
31 General supportive care
32 Side effects
34 Key points
Treatment for AML and its subtypes will be in phases. The goal of treatment is to put the cancer in remission. This chapter provides a general overview of some therapies you might receive and what to expect. Together, you and your care team will choose a treatment plan that is best for your type of AML.

Care team

Those with AML should seek treatment at cancer centers experienced in treating AML.

Treating cancer takes a team approach. Treatment decisions will involve a multidisciplinary team (MDT). An MDT is a team of health care and psychosocial care professionals from different professional backgrounds who have knowledge (expertise) and experience with your type of cancer. This team is united in the planning and implementing of your treatment. Ask who will coordinate your care.

Some members of your care team will be with you throughout cancer treatment, while others will only be there for parts of it. Get to know your care team and help them get to know you.

Depending on your diagnosis, your team might include the following specialists:

- **A diagnostic radiologist** reads the results of x-rays and other imaging tests.
- **An interventional radiologist** performs needle biopsies and places intravenous (IV) ports for treatment.
- **A hematologist or hematologic oncologist** is a medical expert in blood diseases and blood cancers.
- **A pathologist or hematopathologist** analyzes the cells, tissues, and organs removed during a biopsy and provides cancer diagnosis, staging, and information about biomarker testing.
- **A medical oncologist** treats cancer in adults using systemic therapy.
- **A radiation oncologist** prescribes and plans radiation therapy to treat cancer.
- **Oncology nurses** provide your hands-on care, like giving systemic therapy, managing your care, answering questions, and helping you cope with side effects.
- **Palliative care nurses and advanced practice providers (APPs)** help provide an extra layer of support with cancer-related symptoms.
- **Residents and fellows** are doctors who are continuing their training, some to become specialists in a certain field of medicine.
- **Nutritionists and dietitians** can provide guidance on what foods are most suitable for your condition.
- **Psychologists and psychiatrists** are mental health experts who can help...
manage issues such as depression, anxiety, or other mental health conditions that can affect how you think and feel.

- **Social workers** help people solve and cope with problems in their everyday lives. Clinical social workers also diagnose and treat mental, behavioral, and emotional issues. The anxiety a person feels when diagnosed with cancer might be managed by a social worker in some cancer centers. They, or other designated professionals, can help navigate the complexities of financial and insurance stresses.

- **A research team** helps to collect research data if you are in a clinical trial. Clinical trials help bring new therapies to patients and advance the treatment for everyone. Consider asking your care team about access to clinical trials.

You know your body better than anyone. Help other team members understand:

- How you feel
- What you need
- What is working and what is not

Keep a list of names and contact information for each member of your team. This will make it easier for you and anyone involved in your care to know whom to contact with questions or concerns.

---

**Systemic therapy**

Systemic therapy works throughout the body. Types include chemotherapy, targeted therapy, and immunotherapy. Systemic therapy might be used alone or with other therapies. Goals of systemic therapy should be discussed before starting treatment. Your preferences about treatment are important. If you have any religious or personal beliefs about certain kinds of treatment, now would be the time to share them with your care team.

**Warnings about supplements and drug interactions**

You might be asked to stop taking or avoid certain herbal supplements when on a systemic therapy. Some supplements can affect the ability of a drug to do its job. This is called a drug interaction. It is critical to speak with your care team about any supplements you may be taking.

Some examples include:

- Turmeric
- Gingko biloba
- Green tea extract
- St. John’s Wort

Certain medicines can also affect the ability of a drug to do its job. Antacids, heart or blood pressure medicine, and antidepressants are just some of the medicines that might interact with a systemic therapy. Therefore, it is very important to tell your care team about any medicines, vitamins, over-the-counter (OTC) drugs, herbals, or supplements you are taking. **Bring a list with you to every visit.**
Chemotherapy

Chemotherapy is the standard of care for treating AML. Chemotherapy kills fast-dividing cells throughout the body, including cancer cells and normal cells. You will be monitored throughout treatment for side effects or other unwanted (adverse) reactions. All chemotherapy drugs may cause severe, life-threatening, or fatal reactions.

Chemotherapy is most often a liquid that is slowly injected into a vein with a needle. The final dose differs between people because it is based on body weight. Intrathecal chemotherapy is injected into spinal or brain fluid.

In most cases, chemotherapy is given in cycles of treatment days followed by days of rest. This allows the body to recover before the next cycle. Cycles vary in length depending on which chemotherapy is used. You might spend time in the hospital during treatment.

Types of chemotherapy

There are many types of chemotherapy used to treat AML. Often chemotherapies are combined. This is called multi-agent chemotherapy or a multi-agent regimen. Each chemotherapy works to kill cancer cells in a different way, which helps prevent the cancer from coming back. Each type of chemotherapy can also cause different side effects. Talk to the care team about the types of chemotherapy you will be given, when you will get them, and what side effects to expect.

There are 2 types of chemotherapy used to treat AML:

- Anthracyclines damage and disrupt the making of DNA causing cell death of both cancerous and non-cancerous cells.
- Antimetabolites prevent the “building blocks” of DNA from being used.

For chemotherapy examples, see Guide 2.

Anthracyclines

Some anthracyclines can cause heart issues. They may not be an option for you. There is a limit to how much you can receive in your lifetime.

Cytarabine

Cytarabine or Ara-C is used in many treatment regimens. It might be used alone or in combination with other drugs. It might be given as a single dose to reduce a very high white blood cell count.

There are different doses for cytarabine:

- Standard
- High (HiDAC)
- Intermediate
- Low (LDAC)

The dose you will receive is based on many factors. Ask your care team for the details of your treatment.

- What is the dose?
- How often is treatment received?
- How many treatment cycles are needed?
- Will I need to spend time in the hospital? If so, for how long?
Cytarabine or methotrexate may be used to treat AML in the fluid that surrounds the spine or brain. In this case, it is injected into the spinal fluid. This is called intrathecal chemotherapy.

**Hypomethylating agents**

Methyl groups are molecules that are found in DNA. They can turn genes on or off. Leukemia cells often have too many methyl groups. These extra groups can block genes from being turned on and off. Hypomethylating agents (HMAs) block methyl groups from binding to DNA. They turn silenced genes back on, which allows leukemic blasts to mature.

---

### Guide 2

**Chemotherapy examples**

<table>
<thead>
<tr>
<th>Anthracyclines</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Daunorubicin (Cerubidine)</td>
</tr>
<tr>
<td>• Idarubicin (Idamycin PFS)</td>
</tr>
<tr>
<td>• Mitoxantrone (Novantrone)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Antimetabolites</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Cladribine (Leustatin)</td>
</tr>
<tr>
<td>• Clofarabine (Clolar)</td>
</tr>
<tr>
<td>• Cytarabine (Cytosar-U)</td>
</tr>
<tr>
<td>• Fludarabine (Fludara)</td>
</tr>
<tr>
<td>• Methotrexate</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hypomethylating agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Azacitidine (Vidaza)</td>
</tr>
<tr>
<td>• Decitabine (Dacogen)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Dual-drug liposome of cytarabine and daunorubicin (CPX-351 or Vyxeos) includes an antimetabolite and an anthracycline</td>
</tr>
<tr>
<td>• Glasdegib</td>
</tr>
</tbody>
</table>

---

Did you know?

The terms “chemotherapy” and “systemic therapy” are often used interchangeably, but they are not the same. Chemotherapy, targeted therapy, and immunotherapy are all types of systemic therapy.
Targeted therapy

Targeted therapy is a form of systemic therapy that focuses on specific or unique features of cancer cells. Targeted therapies seek out how cancer cells grow, divide, and move in the body. These drugs stop the action of molecules that help cancer cells grow and/or survive.

You will be monitored throughout treatment for side effects or other unwanted (adverse) reactions. As with other systemic therapies, targeted therapy may cause severe, life-threatening, or fatal reactions.

Some examples of targeted therapies:

- Enasidenib (Idhifa) – An inhibitor of the altered IDH2 protein
- Gemtuzumab ozogamicin (Mylotarg) – An antibody targeting cell surface protein CD33
- Gilteritinib (Xospata) – An inhibitor of the altered FLT3 protein
- Ivosidenib (Tibsovo) – An inhibitor of the altered IDH1 protein
- Midostaurin (Rydapt) – An inhibitor of the altered FLT3 protein
- Sorafenib (Nexavar) – An inhibitor of the altered FLT3 protein
- Venetoclax (Venclexta) – An inhibitor of the pro-leukemic protein BCL2

CD33

Gemtuzumab ozogamicin (GO) is a type of targeted therapy that is linked to a chemotherapy drug. It attaches to a cell surface protein called CD33, then enters the cell. Once inside, chemotherapy is released. Many leukemic blasts have CD33 proteins. Mature blood cells do not have CD33 and are not affected. GO may delay blood count recovery and cause liver issues.

Core binding factor

Core binding factor (CBF) creates a shortage of all types of mature blood cells. Gemtuzumab ozogamicin might be used in combination with daunorubicin and cytarabine to treat AML with CBF or other genetic abnormalities.

FLT3

Gilteritinib or midostaurin is used to treat AML with FLT3-ITD and FLT3-TKD gene mutations. Sorafenib alone or with azacitidine or decitabine might be used to treat AML with FLT3-ITD mutation.

IDH1 and IDH2

Ivosidenib and olutasidenib are used to treat AML with IDH1 mutation. Enasidenib is used to treat AML with IDH2 mutation.
Clinical trials

A clinical trial is a type of medical research study. After being developed and tested in a laboratory, potential new ways of treating cancer need to be studied in people. If found to be safe and effective in a clinical trial, a drug, device, or treatment approach may be approved by the U.S. Food and Drug Administration (FDA).

Everyone with cancer should carefully consider all of the treatment options available for their cancer type, including standard treatments and clinical trials. Talk to your doctor about whether a clinical trial may make sense for you.

Phases

Most cancer clinical trials focus on treatment. Treatment trials are done in phases.

- **Phase I trials** study the dose, safety, and side effects of an investigational drug or treatment approach. They also look for early signs that the drug or approach is helpful.

- **Phase II trials** study how well the drug or approach works against a specific type of cancer.

- **Phase III trials** test the drug or approach against a standard treatment. If the results are good, it may be approved by the FDA.

- **Phase IV trials** study the long-term safety and benefit of an FDA-approved treatment.

Finding a clinical trial

**In the United States**

NCCN Cancer Centers  
NCCN.org/cancercenters

The National Cancer Institute (NCI)  
cancer.gov/about-cancer/treatment/clinical-trials/search

**Worldwide**

The U.S. National Library of Medicine (NLM)  
clinicaltrials.gov

**Need help finding a clinical trial?**

NCI’s Cancer Information Service (CIS)  
1.800.4.CANCER (1.800.422.6237)  
cancer.gov/contact
Who can enroll?

Every clinical trial has rules for joining, called eligibility criteria. The rules may be about age, cancer type and stage, treatment history, or general health. These requirements ensure that participants are alike in specific ways and that the trial is as safe as possible for the participants.

Informed consent

Clinical trials are managed by a group of experts called a research team. The research team will review the study with you in detail, including its purpose and the risks and benefits of joining. All of this information is also provided in an informed consent form. Read the form carefully and ask questions before signing it. Take time to discuss with family, friends, or others whom you trust. Keep in mind that you can leave and seek treatment outside of the clinical trial at any time.

Start the conversation

Don’t wait for your doctor to bring up clinical trials. Start the conversation and learn about all of your treatment options. If you find a study that you may be eligible for, ask your treatment team if you meet the requirements. If you have already started standard treatment you may not be eligible for certain clinical trials. Try not to be discouraged if you cannot join. New clinical trials are always becoming available.

Frequently asked questions

There are many myths and misconceptions surrounding clinical trials. The possible benefits and risks are not well understood by many with cancer.

Will I get a placebo?

Placebos (inactive versions of meal medicines) are almost never used alone in cancer clinical trials. It is common to receive either a placebo with a standard treatment, or a new drug with a standard treatment. You will be informed, verbally and in writing, if a placebo is part of a clinical trial before you enroll.

Do I have to pay to be in a clinical trial?

Rarely. It depends on the study, your health insurance, and the state in which you live. Your treatment team and the research team can help determine if you are responsible for any costs.
Hematopoietic cell transplant

A hematopoietic cell transplant (HCT) replaces hematopoietic stem cells that have been destroyed by high doses of chemotherapy and/or radiation therapy (RT) as part of the transplant process. A hematopoietic stem cell is an immature cell that can develop into any type of blood cell. You might hear it called a stem cell transplant (SCT) or a bone marrow transplant (BMT). This book will refer to it as HCT. HCTs are performed in specialized centers.

There are 2 types of HCTs:

- **Autologous** – stem cells come from you and is not used very often in AML.
- **Allogeneic** – stem cells come from a donor who may or may not be related to you.

### Allogeneic transplant

An allogeneic hematopoietic cell transplant (alloHCT) uses healthy stem cells from a donor. The donor may or may not be related to you. Before an HCT, treatment is needed to destroy bone marrow cells. This is called conditioning and it creates room for the healthy donor stem cells. It also weakens the immune system so your body won’t kill the transplanted cells. Chemotherapy is used for conditioning. Radiation therapy may also be given as part of conditioning treatment.

After conditioning, you will receive a transfusion of the healthy stem cells from a donor matched to you. A transfusion is a slow injection of blood products into a vein. This can take several hours. The transplanted stem cells will travel to your bone marrow and grow. New, healthy blood cells will form. This is called engraftment. It usually takes about 2 to 4 weeks. Until then, you will have little or no immune defense. You may need to stay in a very clean room at the hospital or be given antibiotics to prevent or treat infection. Transfusions are also possible. A red blood cell transfusion is used to prevent bleeding and to treat anemia (below normal red blood cell count). A platelet transfusion is used to treat a low platelet count or bleeding. While waiting for the cells to engraft, you will likely feel tired and weak.

### Possible side effects

Every treatment has side effects. You will be monitored for infections, disease relapse, and graft-versus-host disease (GVHD). In GVHD, the donor cells attack your normal, healthy tissue. There are treatments for GVHD. Ask your care team about the possible side effects or complications of HCT and how this might affect your quality of life.

More information on ALL-type induction therapies is available at NCCN.org/patientguidelines and on the NCCN Patient Guides for Cancer app.
Steroids
Steroid is the short name for corticosteroid. Steroids are human-made versions of hormones made by the adrenal glands. The adrenal glands are small structures found near the kidneys, which help regulate blood pressure and reduce inflammation. Steroids can cause short-term and long-term side effects. Corticosteroids are not the same as the steroids used by some athletes.

Radiation therapy
Radiation therapy (RT) uses high-energy radiation from photons, electrons, x-rays, or protons, and other sources to kill cancer cells. It is given over a certain period of time. RT can be given alone or with certain systemic therapies. It may be used as supportive care to help ease pain or discomfort caused by some cancers or to treat leukemia found outside of the bone marrow (extramedullary). Those with leukemia in the central nervous system (CNS) may receive radiation to the brain area.

General supportive care
Supportive care will be specific to your needs. Supportive care is health care that relieves symptoms caused by cancer or its treatment and improves quality of life. It might include pain relief, palliative care, emotional or spiritual support, financial aid, or family counseling. Tell your care team how you are feeling and about any side effects so they can be managed. Best supportive care, supportive care, and palliative care are often used interchangeably.

It is very important to take care of yourself by eating well, drinking plenty of fluids, exercising, and doing things that make you feel energized. Strength is needed to sustain you during treatment. Some potential side effects and procedures are described next. They are not listed in order of importance. Some side effects are very rare.

Side effects
All cancer treatments can cause unwanted health issues called side effects. Side effects depend on many factors. These factors include the drug type and dose, length of treatment, and the person. Some side effects may be harmful to your health. Others may just be unpleasant. AML treatment can cause a number of side effects. Some are very serious.

More information on supportive care is available at NCCN.org/patientguidelines and on the NCCN Patient Guides for Cancer app.
Ask for a complete list of side effects of your treatments. Also, tell your treatment team about any new or worsening symptoms. There may be ways to help you feel better. There are also ways to prevent some side effects. You will be monitored closely for side effects.

**Late effects**

Late effects are side effects that occur months or years after a disease is diagnosed or after treatment has ended. Late effects may be caused by cancer or cancer treatment. They may include physical, mental, and social problems, and second cancers. The sooner late effects are treated the better. Ask your care team about what late effects could occur. This will help you know what to look for.

**Survivorship**

A person is a cancer survivor from the time of diagnosis until the end of life. When treatment leads to remission (or no evidence of disease), you will need follow-up or survivorship care for late effects. During survivorship care you will still have a care team, but it will look different. Seek out peer support groups, whether online or in-person.

---

**Side effects**

**Anemia, neutropenia, and thrombocytopenia**

Some cancer treatments can cause low blood cell counts.

- **Anemia** is a condition where your body does not have enough healthy blood cells, resulting in less oxygen being carried to your cells. You might tire easily if you are anemic.
- **Neutropenia** is a decrease in neutrophils, a type of white blood cell. This puts you at risk for infection.
- **Thrombocytopenia** is a condition where there are not enough platelets found in the blood. This puts you at risk for bleeding.

**Blood clots**

Cancer treatment can cause blood clots to form. This can block blood flow and oxygen in the body. Blood clots can break loose and travel to other parts of the body causing stroke or other problems.

**Diarrhea**

Diarrhea is frequent and watery bowel movements. Your care team will tell you how to manage diarrhea. It is important to drink lots of fluids.
Difficulty eating

Sometimes side effects from surgery, cancer, or its treatment might cause you to feel not hungry or sick to your stomach (nauseated). You might have a sore mouth. Healthy eating is important during treatment. It includes eating a balanced diet, eating the right amount of food, and drinking enough fluids. A registered dietitian who is an expert in nutrition and food can help. Speak to your care team if you have trouble eating or maintaining weight.

Distress

Depression, anxiety, and sleeping problems are common and are a normal part of cancer diagnosis. Talk to your care team and with those whom you feel most comfortable about how you are feeling. There are services, people, and medicine that can help you. Support and counseling services are available.

Fatigue

Fatigue is extreme tiredness and inability to function due to lack of energy. Fatigue may be caused by cancer or it may be a side effect of treatment. Let your care team know how you are feeling and if fatigue is getting in the way of doing the things you enjoy. Eating a balanced diet, exercise, yoga, and massage therapy can help. You might be referred to a nutritionist or dietitian to help with fatigue.

Nausea and vomiting

Nausea and vomiting are common side effects of treatment. You will be given medicine to prevent nausea and vomiting.

Neuropathy

Neuropathy is a nerve problem that causes pain, numbness, tingling, swelling, or muscle weakness in different parts of the body. It usually begins in the hands or feet and gets worse over time. Neuropathy may be caused by cancer or cancer treatment. Most of the time, neuropathy goes away after treatment.

Neurotoxicity

Some treatments can damage the nervous system (neurotoxicity) causing problems with concentration, memory, and thinking. Seizures and confusion can occur.

Pain

Tell your care team about any pain or discomfort. You might meet with a palliative care specialist or with a pain specialist to manage pain.
Key points

- Treatment decisions should involve a multidisciplinary team (MDT) of health care and social care professionals from different fields of medicine who have knowledge (expertise) and experience with your type of cancer.

- Your care team will plan treatment based on your age and other factors such as your overall health and performance status. Performance status is your general level of fitness.

- Your preferences about treatment are always important.

- Systemic therapy works throughout the body. AML is treated with systemic therapy.

- A hematopoietic cell transplant (HCT) replaces damaged bone marrow stem cells with healthy stem cells. You might hear it called a stem cell transplant (SCT) or bone marrow transplant (BMT).

- A clinical trial is a type of research that studies a treatment to see how safe it is and how well it works.

- Supportive care is health care that relieves symptoms caused by cancer or its treatment and improves quality of life. Supportive care is always given.

- All cancer treatments can cause unwanted health issues called side effects. It is important for you to tell your care team about all your side effects so they can be managed.

- Eating a balanced diet, drinking enough fluids, and exercise can help manage side effects.
4

AML

36 Overview
36 Treatment phases
37 Treatment overview
39 Intensive induction
40 Less intensive induction
42 After induction
42 Maintenance
42 Surveillance
43 Relapsed and refractory
44 Supportive care
47 Key points
There are different types of AML. This chapter is for those with AML that is not APL or BPDCN. It is sometimes referred to as non-APL AML. Together, you and your care team will choose a treatment plan that is best for you.

Overview

There are different types of AML. Most people with leukemia do not have acute promyelocytic leukemia (APL). This chapter is for those with non-APL AML.

Diagnosis

To be diagnosed with AML, myeloblasts must be present in the bone marrow or blood. At diagnosis, most people will have a bone marrow aspirate and biopsy. Some may have a lumbar puncture if there are signs and symptoms of central nervous system (CNS) leukemia.

What causes AML?

AML can happen for certain known reasons, but very often there is no clear cause that can be determined. Certain treatments for other cancers, such as radiation or a certain type of chemotherapy, can later cause AML. Myelodysplastic syndrome (MDS) or other chronic marrow cancers can become AML. MDS is a type of cancer that occurs when bone marrow stops making enough healthy blood cells and abnormal cells are found. AML can also run in certain families, although this is thought to be quite uncommon.

Treatment phases

The goal of the induction phase of treatment is to put AML into complete remission. In complete remission, both bone marrow and blood cell blasts are suppressed, allowing normal marrow function to resume. However, undetected leukemia cells may persist and can return causing relapse. Consolidation therapy is needed to prolong remission.

There are different types of treatment responses. When there are no signs of cancer, it is called a complete response (CR) or complete remission. This does not always mean that AML has been cured. Remission can be short-term (temporary) or long-lasting (permanent). Partial remission (PR) and a complete response with partial hematologic (CRh) or incomplete (CRi) blood recovery are also possible. Ask your care team what these terms might mean for your type of AML.

It takes time for bone marrow to make normal blood cells again. This is called recovery.

In complete remission:
- There is no sign of leukemia after treatment
- Your blood counts have returned to normal
- You have less than 5 percent (5%) blasts in your bone marrow (or fewer than 5 blasts out of every 100 blood cells)

Treatment for AML can occur over years. The several phases are described next.
AML » Treatment overview

Induction

Induction is the first phase of treatment. It is also called remission induction. The goal is to reduce the number of blasts and put AML in remission. As the number of blasts decreases, other types of marrow cells will also decrease. Your marrow will need time to recover, about 4 to 6 weeks, so blood cells can return to normal levels. Treatment attempts to restore the process of making normal blood cells. When blood counts are normal, bone marrow tests will be repeated to see if the leukemia is in remission.

If treatment does not reduce the number of blasts, you may receive more treatment called re-induction. If blasts persist after more induction, treatment options will be under relapse.

Minimal or measurable residual disease

In minimal or measurable residual disease (MRD) very sensitive lab tests, such as PCR, find leukemia cells in your bone marrow. When testing finds MRD, it is called a positive MRD result or MRD positive (MRD+). Ask your care team what this might mean and what the next steps will be.

Consolidation

Your blood will be given time to recover before starting consolidation. Consolidation is the second phase of treatment. It is also called post-remission therapy. Consolidation treats blasts that may have survived induction.

Monitoring

You will have frequent blood tests during induction and consolidation. Bone marrow tests are possible.

Maintenance

For some people, maintenance is the final phase of treatment. The goal is to prolong remission, and the treatment may be received for months to years.

Surveillance

Surveillance watches for any changes in your condition after remission or a hematopoietic cell transplant (HCT). You will have tests during surveillance to check for relapse.

Treatment overview

AML is not treated the same for everyone. As the body ages, it can have difficulty tolerating higher doses or more intense cancer treatments. In addition to age, your overall health, general level of fitness (performance status), and genetic risk play a role in treatment decisions. Some cancers like AML are treated more aggressively than others. An intensive therapy might have more side effects or be of a higher dose than a less intensive therapy. An intensive therapy is not necessarily better. Remission or a complete response is still possible in lower-intensity treatments.

There are always risks with treatment. Talk with your care team about the risks and why a certain treatment might be better for you. Find out how treatment might affect your quality and length of life. Your preferences about treatment are also important.
**Risk groups**

Risk groups for non-APL AML are based on the presence of abnormal or mutated genes. Risk groups are used to make decisions about treatment and to gain information about the likely course your cancer will take. This is called a prognosis. Some people may do better than expected. Some will do worse. Risk groups will be used in addition to other factors, such as your age and overall health, to plan treatment. See Guide 3.

Some treatments are based on risk groups while others are specific to an AML subtype such as:

- Therapy-related AML (AML caused by an earlier treatment for a different cancer)
- Those who had myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) before called antecedent MDS or CMML
- AML with myelodysplasia-related changes called AML-MRC

### Guide 3
**AML risk groups**

<table>
<thead>
<tr>
<th>Category</th>
<th>Abnormal Genes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Favorable</strong></td>
<td>Includes any of the following abnormal genes:</td>
</tr>
<tr>
<td></td>
<td>• t(8;21)(q22;q22.1) or RUNX1::RUNX1T1</td>
</tr>
<tr>
<td></td>
<td>• inv(16)(p13.1q22) or t(16;16)(p13.1q22) or CBFB::MYH11</td>
</tr>
<tr>
<td></td>
<td>• Mutated NPM1 without FLT3-ITD</td>
</tr>
<tr>
<td></td>
<td>• bZIP in-frame mutated CEBPA</td>
</tr>
<tr>
<td><strong>Intermediate</strong></td>
<td>Includes any of the following abnormal genes:</td>
</tr>
<tr>
<td></td>
<td>• Mutated NPM1 and FLT3-ITD</td>
</tr>
<tr>
<td></td>
<td>• Wild-type NPM1 with FLT3-ITD (without adverse-risk genetic lesions)</td>
</tr>
<tr>
<td></td>
<td>• t(9;11)(p21.3;q23.3) or MLLT3::KMT2A</td>
</tr>
<tr>
<td></td>
<td>• Other abnormalities not classified as favorable or adverse</td>
</tr>
<tr>
<td><strong>Poor</strong></td>
<td>Includes any of the following abnormal genes:</td>
</tr>
<tr>
<td></td>
<td>• t(6;9)(p23;q34.1) or DEK::NUP214</td>
</tr>
<tr>
<td></td>
<td>• t(v;11q23.3) or KMT2A-rearranged</td>
</tr>
<tr>
<td></td>
<td>• t(9;22)(q34.1;q11.2) or BCR::ABL1</td>
</tr>
<tr>
<td></td>
<td>• inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2) or GATA2, MECOME(EVI1)</td>
</tr>
<tr>
<td></td>
<td>• 25 or del(5q) or 27 or 217/abn(17p)</td>
</tr>
<tr>
<td></td>
<td>• Complex karyotype, monosomal karyotype</td>
</tr>
<tr>
<td></td>
<td>• Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2</td>
</tr>
<tr>
<td></td>
<td>• Mutated TP53</td>
</tr>
</tbody>
</table>
Intensive induction

Favorable and intermediate risk

Intensive induction options for favorable and intermediate risk groups can be found in Guide 4.

The standard 7 + 3 induction regimen is:

- 7 days of cytarabine with
- 3 days of an anthracycline (idarubicin or daunorubicin)

Guide 4

Favorable and intermediate risk groups: Intensive induction options

**Favorable-risk AML**

Preferred:
- Standard 7+3 (daunorubicin) with gemtuzumab ozogamicin if CD33 positive

Other recommended:
- Standard 7+3 (daunorubicin or idarubicin)
- 7+3 (mitoxantrone) for those 60 years of age and over
- FLAG-IDA with gemtuzumab ozogamicin (GO). FLAG-IDA includes fludarabine, high-dose cytarabine (HiDAC), granulocyte colony-stimulating factor (G-CSF), and idarubicin

**AML with FLT3-ITD or FLT3-TKD mutation**

- Standard 7+3 (daunorubicin) with midostaurin

**Intermediate-risk AML**

Preferred:
- Standard 7+3 (daunorubicin or idarubicin)
- 7+3 (mitoxantrone) for those 60 years of age and over

Other recommended:
- Standard 7+3 (daunorubicin or idarubicin) with gemtuzumab ozogamicin if CD33 positive
- FLAG-IDA with gemtuzumab ozogamicin
Poor risk

Intensive induction options for poor risk groups can be found in **Guide 5**.

Less intensive induction

Not everyone wants or can tolerate intensive induction treatment. Age, overall health, and disease features play an important role. Less intensive induction therapy can still cause a complete response.

Treatment options are based on the presence or absence of certain actionable gene mutations. An actionable mutation is one that is likely to respond to a targeted therapy.

Actionable mutations include **FLT3**, **IDH1**, and **IDH2**. Treatment options for both actionable mutations and AML without actionable mutations can be found in **Guide 6**.

### Guide 5

**Poor risk groups: Intensive induction options**

| Poor-risk AML with or without **TP53** mutation or del17p abnormality | • Standard 7+3 (daunorubicin or idarubicin)  
• 7+3 (mitoxantrone) for those 60 years of age and over  
• HiDAC (idarubicin or daunorubicin) with etoposide  
• FLAG-IDA (fludarabine, high-dose cytarabine, G-CSF, and idarubicin)  
• Decitabine with venetoclax  
• Azacitidine with venetoclax  
• LDAC with venetoclax  
• Low-intensity therapy (azacitidine or decitabine) |
| --- | --- |
| Therapy-related AML (other than core binding factor AML), antecedent MDS, CMML, or AML-MRC | • Standard 7+3 (daunorubicin or idarubicin)  
• CPX-351/dual-drug liposomal cytarabine and daunorubicin  
• Decitabine with venetoclax  
• Azacitidine with venetoclax  
• LDAC with venetoclax  
• Low-intensity therapy (azacitidine or decitabine) |
Guide 6
Less intensive induction options based on mutation

<table>
<thead>
<tr>
<th>AML without actionable mutations</th>
<th>Preferred:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Azacitidine with venetoclax</td>
</tr>
<tr>
<td></td>
<td>• Decitabine with venetoclax</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>AML without actionable mutations</th>
<th>Other recommended:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• LDAC with venetoclax</td>
</tr>
<tr>
<td></td>
<td>• Azacitidine or decitabine</td>
</tr>
<tr>
<td></td>
<td>• Glasdegib with LDAC</td>
</tr>
<tr>
<td></td>
<td>• Gemtuzumab ozogamicin (GO) for CD33 positive</td>
</tr>
<tr>
<td></td>
<td>• LDAC</td>
</tr>
<tr>
<td></td>
<td>• Best supportive care (hydroxyurea and transfusion support)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IDH1 or IDH2 mutation</th>
<th>Preferred:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Azacitidine and venetoclax</td>
</tr>
<tr>
<td></td>
<td>• Ivosidenib with azacitidine (<em>IDH1</em> only)</td>
</tr>
<tr>
<td></td>
<td>• Decitabine with venetoclax</td>
</tr>
<tr>
<td></td>
<td>• Ivosidenib (<em>IDH1</em> only)</td>
</tr>
<tr>
<td></td>
<td>• Enasidenib (<em>IDH2</em> only)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IDH1 or IDH2 mutation</th>
<th>Other recommended:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• LDAC with venetoclax</td>
</tr>
<tr>
<td></td>
<td>• Azacitidine or decitabine</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FLT3 mutation</th>
<th>Preferred:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Azacitidine with venetoclax</td>
</tr>
<tr>
<td></td>
<td>• Decitabine with venetoclax</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FLT3 mutation</th>
<th>Other recommended:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• LDAC with venetoclax</td>
</tr>
<tr>
<td></td>
<td>• Azacitidine, decitabine, or sorafenib</td>
</tr>
<tr>
<td></td>
<td>• Azacitidine or decitabine and sorafenib. (<em>Sorafenib is used in FLT3-ITD mutated AML</em>)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FLT3 mutation</th>
<th>Used in some cases:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Gilteritinib with azacitidine</td>
</tr>
</tbody>
</table>
After induction

Your next round of induction will be based on which therapy you had first and how AML responded to treatment. Treatment options are based on the amount of cancer or blasts that remain after induction called minimal or measurable residual disease (MRD). In hypoplasia, bone marrow is starting to recover, but hasn't fully recovered yet. A lumbar puncture might be done. Further treatment is based on if there was a complete response or less than a complete response to induction.

- If there was a complete response (remission), then consolidation can begin. Consolidation is often a cytarabine-based therapy, a continuation of a previous therapy, or a hematopoietic cell transplant (HCT).
- If there was less than a complete response or cancer progressed, then options include chemotherapy, targeted therapy, a clinical trial, an HCT, or best supportive care. Best supportive care is treatment to improve quality of life and relieve discomfort.

Cytarabine or Ara-C is used in many treatment regimens. Dosing might be:
- Standard
- High (HiDAC)
- Intermediate
- Low (LDAC)

Surveillance

Surveillance is a period of testing that begins after remission to monitor for relapse or the return of cancer. During surveillance, you will have a complete blood count (CBC) every 1 to 3 months for 2 years. After that, a CBC should be repeated every 3 to 6 months for up to 5 years. A bone marrow aspirate and biopsy may be needed.

Maintenance

Not everyone will receive maintenance therapy. If given, it will likely be azacitidine, a chemotherapy. For those who had an HCT, then maintenance might be a targeted therapy.
Relapsed and refractory

When leukemia returns it is called a relapse. The goal of treatment is to achieve remission again. You may receive treatment to prevent the blasts from spreading to your brain and spine. A search for a blood stem (hemapoietic) cell donor should begin at first relapse, if this is an option being considered.

When leukemia does not respond to treatment or worsens during treatment, it is called refractory or resistant cancer. The cancer may be resistant at the start of treatment or it may become resistant during treatment. Biomarker testing (including IDH1, IDH2, and FLT3 mutations) should be done to determine next treatment options.

For relapsed AML or AML that stops responding to treatment after consolidation, options include:

- Clinical trial (strongly preferred)
- Targeted therapy (Guide 7) or chemotherapy followed by an HCT (either matched sibling or another donor)
- Repeat initial successful induction regimen if 12 months or more since induction regimen
- Best supportive care

Guide 7
Targeted therapy based on mutation

<table>
<thead>
<tr>
<th>AML with FLT3-ITD mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Gilteritinib</td>
</tr>
<tr>
<td>• Hypomethylating agents (HMAs) such as azacitidine or decitabine with sorafenib</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>AML with FLT3-TKD mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Gilteritinib</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>AML with IDH1 mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Ivosidenib</td>
</tr>
<tr>
<td>• Olutasidenib</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>AML with IDH2 mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Enasidenib</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CD33-positive AML</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Gemtuzumab ozogamicin</td>
</tr>
</tbody>
</table>
Supportive care

Supportive care aims to improve your quality of life. It includes care for health issues caused by cancer or cancer treatment. It is sometimes called palliative care.

All cancer treatments can cause unwanted health issues called side effects. Some side effects are very serious. Ask your treatment team for a complete list of side effects of your treatments. Also, tell your treatment team about any new or worsening symptoms. There may be ways to help you feel better. There are also ways to prevent some side effects.

Supportive care for AML treatment-related side effects are described next.

**Abnormal blood cell counts**

Before treatment, your white blood cell count may be very high. A high count can cause severe health issues. Apheresis or hydroxyurea can quickly reduce the count. Apheresis is a procedure in which blood is collected, certain types of cells are removed, and your blood is returned to your body.

**Blood transfusions**

A blood transfusion replaces blood or blood components such as red blood cells or platelets. During treatment, you may need blood transfusions. A blood transfusion is a routine procedure where donated blood is given through a vein in your arm. A blood transfusion typically takes 1 to 4 hours, depending on how much is needed and what part of the blood you need.

In those with AML receiving a blood transfusion, most of the white blood cells will be removed from donor blood. If treatment will suppress your immune system, then donor blood will also be treated with radiation. These steps will help prevent donor blood from attacking your body. They will also help prevent infections.

**Those who do not want blood transfusions**

Treatment without blood transfusions is sometimes referred to as bloodless or transfusion-free care. Treatment of AML requires the use of blood and blood products for supportive care. If you do not wish to receive transfusions or certain blood products, please make your wishes known.

If you do not want blood transfusions, your care team will:

- Minimize blood loss and the risk of bleeding.
- Discuss goals of care and complications without transfusion.
- Ask if certain blood products can be used under certain circumstances.
Discuss if stem cells (from you or a donor who may or may not be related to you) will be acceptable.

Avoid medicines or procedures that can increase the risk of bleeding or myelosuppression. In myelosuppression, bone marrow activity is decreased, resulting in fewer red blood cells, white blood cells, and platelets.

Consider using vitamin K or other options for those at risk of bleeding or to manage bleeding.

Consider using acetaminophen to manage fever.

Consider iron, folate, and vitamin B12 supplementation. Iron supplementation may be avoided in someone with excess iron levels.

Consider use of erythropoiesis-stimulating agent (ESA), granulocyte colony-stimulating factor (G-CSF), and thrombopoietin (TPO) after a thorough discussion of potential risks, benefits, and uncertainties.

Consider bed rest and supplemental oxygen in those with severe anemia.

Based on your disease, your care team might:

- Test for actionable mutations and consider use of targeted therapies instead of intensive chemotherapy.
- Consider use of less myelosuppressive induction including dose reduction of anthracyclines, and use of non-intensive chemotherapy.
- Consider referring to centers with experience in bloodless autologous (self) hematopoietic cell transplant.

### Transfusions

A transfusion is a common procedure to replace blood or blood components (red blood cells or platelets). It is given through an intravenous line (IV), a tiny tube that is inserted into a vein with a small needle.

- The whole process can take about 1 to 4 hours, depending on how much blood is needed.
- Most transfusions use blood from a donor.
- Blood transfusions are usually very safe. Donated blood is carefully tested, handled, and stored.
- Most people's bodies handle blood transfusions very well. But, like any medical procedure, there are some risks. Speak with your care team for specific information about the risks.
- Systemic therapy can affect how bone marrow makes new blood cells. Some people getting treatment for cancer might need a transfusion of red blood cells or platelets.
Brain impairment

Cytarabine can affect the part of the brain that coordinates movement. Symptoms include constant eye movement that can’t be controlled. You may be unable to control the range of movement by your legs or arms. Your speech may become slurred.

Differentiation syndrome

Differentiation syndrome is a potentially serious side effect of taking certain anti-cancer drugs. It is caused by a large, fast release of cytokines (an immune protein) as the leukemia cells respond to treatment. Differentiation syndrome used to be called retinoic acid syndrome.

- Symptoms include fever, swelling in limbs, and trouble breathing. You can also gain weight and get a skin rash.
- Signs include low blood pressure and a decrease in blood oxygen levels. Fluid can build up around your lungs or heart. Damage to your kidneys and liver may occur.

Treatment must be started at the first signs or symptoms. Steroids are one effective option for treatment. If there is a rising white blood cell count with differentiation, then an antimetabolite called hydroxyurea (Hydrea) is also frequently used.

Eye issues

High-dose cytarabine may cause the white part of your eyes to become red. Your eyes may feel painful and make more tears. These issues may be prevented with saline or steroid eye drops.

Growth factors

Growth factors, called granulocyte colony-stimulating factor (G-CSF), trigger the bone marrow to make granulocytes (white blood cells). It is sometimes part of an aggressive chemotherapy regimen for relapsed or refractory cancer. Growth factors are an option for supportive care during consolidation if you have a life-threatening infection. Filgrastim (Neupogen) is a G-CSF.

A biosimilar or substitute might be used in place of filgrastim. A biosimilar is almost an identical drug made by another company. It is used in the exact same way and at the same dose as filgrastim.

Infections

If not treated early, infections can be fatal. Infections can be caused by viruses, fungus, or bacteria. Antibiotics can treat bacterial infections. Anti-fungals can treat fungal infections. You may be given drugs to prevent infections.

Tumor lysis syndrome

In tumor lysis syndrome (TLS), waste released by dead cells builds up in the body causing kidney damage and severe blood electrolyte disturbances. TLS can be life threatening.

Induction chemotherapy may cause TLS. TLS is more likely if your blast count is very high.
Key points

- Most people with AML have a subtype other than APL.
- Treatment for AML involves several phases.
- Chemotherapy is a key part of treatment. Targeted therapy may be added if certain gene mutations are present.
- The goal of treatment is a complete response (CR) or remission.
- Minimal or measurable residual disease (MRD) is AML that appears to be in remission, but very sensitive tests find leukemia cells in your bone marrow.
- Monitoring watches for any changes in your condition.
- Leukemia that returns after remission is called relapse.
- When leukemia does not respond to treatment or worsens during treatment, it is called refractory or resistant cancer.
- Supportive care can help to prevent or relieve side effects caused by AML or its treatment and improve quality of life.
- Treatment of AML requires the use of blood and blood products for supportive care. If you do not wish to receive transfusions or certain blood products, please make your wishes known.

We want your feedback!

Our goal is to provide helpful and easy-to-understand information on cancer.

Take our survey to let us know what we got right and what we could do better.

NCCN.org/patients/feedback
Acute promyelocytic leukemia (APL) is a rare type of AML. With treatment, APL is cured more often than other AML types. APL occurs when pieces of chromosomes 15 and 17 break off and trade places creating two fused genes called PML::RARA and RARA::PML. You will be treated for APL if the PML::RARA gene is found. Together, you and your care team will choose a treatment plan that is best for you.

Get to know your care team and help them get to know you.

Overview

Acute promyelocytic leukemia (APL) is a rare type of AML. About 1 out of every 10 people with AML have APL. Without treatment, APL can worsen quickly and be fatal. With treatment, APL is cured more often than other AML types. APL is treated with all-trans retinoic acid (ATRA) in combination with another therapy.

Diagnosis

The initial diagnosis of APL may be confirmed by a test such as FISH or PCR. APL can be diagnosed quickly and treatment started within just a few hours.

APL occurs when parts of chromosome 15 and chromosome 17 break off and trade places, called translocation. This translocation is referred as t(15;17). It makes two genes that are fused together. These two fused genes are called PML::RARA and RARA::PML. You will be treated for APL if the PML::RARA gene is found.

APL can cause bleeding and clotting that can be fatal. You will start taking retinoid (ATRA) right away if your doctor suspects APL. It can stop the bleeding and clotting tendency. If APL is ruled out, then you will stop taking the retinoid.

What causes APL?

In most situations, the causes of APL are not known. Sometimes, certain treatments for other cancers can cause what is known as therapy-related APL.
Treatment phases

Treatment phases for APL include induction, consolidation, and sometimes maintenance. Treatment might take place over a period of years. Some types of treatment may be harmful to your heart. Before treatment, your doctor may test how well your heart is working. You may receive treatment for your heart, too.

Induction

Induction is the first phase of treatment. The goal is to reduce the number of blasts and put APL into remission. Treatment is sometimes called remission induction because the focus of induction is remission or a complete response.

Types of treatment response:

- **A hematologic response** measures your blood cell counts.
- Induction often causes a large drop in the number of blasts. This is called a **morphologic complete response**.
- When the translocation of chromosomes 15 and 17 or t(15;17) is no longer found, it is called a **cytogenetic complete response**.
- **A molecular complete response** will likely follow a cytogenetic response. A molecular response is defined as the absence of the PML::RARA gene. This means the PML::RARA gene is not found using PCR. Often, more treatment is needed to achieve a molecular response.
- When there are no signs or symptoms of cancer, it is called **complete remission**. It might be more specifically described as the type of remission, such as morphologic or molecular remission.

Consolidation

Consolidation is the second phase of treatment. It treats blasts that may have survived induction. Often, consolidation uses the same drugs as before. Consolidation can cause a long-lasting molecular response. You may have a lumbar puncture before starting consolidation.

Maintenance

Maintenance or post-consolidation therapy is the last phase of treatment. The goal is to prolong the results of prior treatment. Chances are you will continue the same treatment, but at a lower dose. Treatment may last for 1 to 2 years or longer. Some APL treatment regimens include maintenance therapy. Ask your care team if your regimen includes maintenance therapy.
Treatment overview

Unlike other types of AML, APL is treated with all-trans retinoic acid (ATRA). Often, ATRA is combined with arsenic trioxide. These treatments are specific to APL. Gemtuzumab ozogamicin (GO), a targeted therapy, might be given. Chemotherapy may also be used.

**ATRA**

ATRA is made in the body from vitamin A, but it is also made in a lab to treat acne and APL. This drug is also called a retinoid. Retinoid forces APL blasts to mature and become normal cells.

Retinoid is an effective treatment for APL. Used by itself it can achieve a complete response (remission) in most people. However, this response is short-lived. Therefore, other treatments must be added to achieve better results.

**Arsenic trioxide (Trisenox)**

Arsenic trioxide (or ATO) causes the death of APL cells. When added to ATRA, it improves outcomes. More leukemia cells die. Relapse occurs in fewer people. Your heart and electrolytes will be monitored during treatment with arsenic trioxide.

Low-risk group

Those with a white blood cell count of 10,000 mcL or less at diagnosis are placed into the low-risk group. For low risk, the preferred induction therapy option is ATRA with arsenic trioxide and supportive care. Consolidation will include ATRA with arsenic trioxide.

If arsenic trioxide is not an option, ATRA with idarubicin or gemtuzumab can be used for induction therapy. Consolidation will be a continuation of induction therapy and might include mitoxantrone.

It takes time for blood to recover. You might have a bone marrow biopsy and aspirate before starting consolidation.
High-risk group

Those with a white blood cell count of more than 10,000 mcL at diagnosis are placed into the high-risk group.

Treatment for high risk is based on if you have:

- No heart issues or heart disease
- Heart issues such as low ejection fraction or prolonged QTc

Treatment for high risk is based on those with and without heart issues or heart disease. In all groups, ATRA is used as part of induction therapy. After induction, a bone marrow aspirate and biopsy will be done to look for and confirm remission. A lumbar puncture might be done.

No heart issues

For high-risk group without heart issues, the preferred induction therapy option is ATRA with arsenic trioxide and either a chemotherapy (idarubicin, cytarabine) or targeted therapy (gemtuzumab). Consolidation will be a continuation of induction therapy and might include mitoxantrone.

High risk with heart issues

For high-risk group with heart issues such as heart disease, induction options are based on the type of heart issue. All induction options include ATRA. Other systemic therapies might be added. Consolidation will be a continuation of induction therapy. A lumbar puncture is possible.

There are 2 types of heart issues that affect treatment:

- Low ejection fraction is when the amount of blood pumping from the left side of the heart is lower than normal. This is measured using a multigated acquisition (MUGA) scan or echocardiogram.
- Prolonged QT interval (or QTc) occurs when your heart muscle takes longer than normal to recharge between beats. Often, this electrical disturbance can be seen on an electrocardiogram (ECG).

Maintenance

If the drug regimen you were started on includes maintenance or post-consolidation therapy, then you may have this last phase of treatment. The goal is to prolong the effective results of prior treatment. Chances are you will continue the same treatment, but at a lower dose.

Monitoring

After completing maintenance therapy, you will enter a monitoring phase. Monitoring is a prolonged period of testing to look for signs that APL has returned, called relapse. PCR tests will be done. Bone marrow or blood samples might be used. You will have no drug therapy during this time.
Relapse

APL can return after remission. A relapse is possible after either a morphologic or molecular response. In relapse after molecular response, the PML::RARA gene has returned. You will have bone marrow and genetic tests to confirm you have relapsed APL and not AML caused by previous treatment (called therapy-related AML).

Treatment for first relapse APL will be based on your prior therapy and if it is:

- Early relapse (less than 6 months after treatment)
- Late relapse (6 or more months after treatment)

The goal of treatment is to achieve remission again. This is not always possible.

Second therapy

After first relapse treatment is complete, your next therapy will be based on if remission was achieved.

If remission before, then the options are:

- A hematopoietic cell transplant (HCT)
- Clinical trial
- Arsenic trioxide

You may receive chemotherapy to prevent APL from spreading to your brain and spine (central nervous system or CNS).

If no remission, then the options are:

- Clinical trial
- HCT (matched sibling or another donor)

Standard of care is the best known way to treat particular disease based on past clinical trials. There may be more than one treatment regimen that is considered standard of care. Ask your care team what treatment options are available and if a clinical trial might be right for you.
Supportive care

Supportive care aims to improve your quality of life. It includes care for health issues caused by cancer or cancer treatment. It is sometimes called palliative care. Tell your treatment team about any new or worsening symptoms.

Supportive care for APL is described next.

**Arsenic trioxide monitoring**

Arsenic trioxide can cause serious irregular heart rhythms (arrhythmias). You will be monitored for a prolonged QT interval. In prolonged QT, the heart muscle takes longer than normal to recharge between beats. This electrical disturbance often can be seen on an electrocardiogram (ECG).

**Bleeding**

APL can cause bleeding, or coagulopathy, that can be fatal. Your blood will be tested to see how well it clots. Bleeding can usually be managed with platelet transfusions, cryoprecipitate, and fresh frozen plasma. Cryoprecipitate comes from thawed frozen blood.

**Differentiation syndrome**

Differentiation syndrome is caused by a large release of cytokines (immune substances) from leukemia cells. Anti-cancer drugs used to treat APL may cause differentiation syndrome. Symptoms of differentiation syndrome include fever, swelling in limbs, and trouble breathing. Weight gain and a skin rash are possible. Signs of differentiation syndrome include low blood pressure and a decrease in blood oxygen. Fluid can build up around your lungs or heart. Damage to your kidneys and liver may occur. This syndrome can be fatal if not caught early.

---

**Key points**

- Acute promyelocytic leukemia (APL) is a rare type of AML. With treatment, APL is cured more often than other AML types.
- APL occurs when pieces of chromosomes 15 and 17 break off and trade places creating two fused genes called \( PML::RARA \) and \( RARA::PML \). You will be treated for APL if the \( PML::RARA \) gene is found.
- APL can cause bleeding that can be fatal. You will start taking retinoid (ATRA) right away if your doctor suspects APL.
- Treatment phases for APL include induction, consolidation, and sometimes maintenance. Treatment might take place over a period of years.
- APL is treated with all-trans retinoic acid (ATRA) in combination with another therapy.
- Supportive care aims to improve quality of life and prevent life-threatening health issues caused by APL or its treatment.
# BPDCN

<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>56</td>
<td>Overview</td>
</tr>
<tr>
<td>57</td>
<td>Testing and diagnosis</td>
</tr>
<tr>
<td>57</td>
<td>Treatment overview</td>
</tr>
<tr>
<td>58</td>
<td>Intensive therapy</td>
</tr>
<tr>
<td>59</td>
<td>No intensive therapy</td>
</tr>
<tr>
<td>59</td>
<td>Relapsed and refractory</td>
</tr>
<tr>
<td>60</td>
<td>Supportive care</td>
</tr>
<tr>
<td>60</td>
<td>Key points</td>
</tr>
</tbody>
</table>
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare, aggressive blood cancer. It is similar to AML. However, unlike AML, BPDCN can be found in blood, bone marrow, lymph nodes, or skin. It is often misdiagnosed. Together, you and your care team will choose a treatment plan that is best for you.

Overview

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is cancer of the immature plasmacytoid dendritic cells (blasts), a type of immune cell. These blood cells start in the bone marrow and travel to the lymphatic organs such as the spleen and lymph nodes. Skin lesions are common. BPDCN can also affect the central nervous system (CNS).

BPDCN occurs in all races. It is often misdiagnosed because the symptoms and signs vary greatly and the disease is rare. Therefore, ideally, your treatment team should include doctors from different fields of medicine who are experts in BPDCN.

You might have BPDCN if you have:

- Skin lesions that might be dark purple and large or small spots across the skin. It might look like a rash or bruises. Everyone is different.
- Enlarged lymph nodes

What causes BPDCN?

Myelodysplastic syndrome (MDS) can become BPDCN. MDS is a type of cancer that occurs when bone marrow stops making enough healthy blood cells and abnormal cells are present. MDS starts in the blood stem cells of bone marrow.

Chronic myelomonocytic leukemia (CMML) can become BPDCN. CMML is a slow-growing type of MDS or myeloproliferative neoplasm (MPN) in which there are too many myelomonocytes, a type of white blood cell, in the bone marrow.

Seek treatment at a center that specializes in BPDCN.
Testing and diagnosis

Almost everyone with BPDCN gets skin lesions. BPDCN is often found through a skin biopsy after a visit to the dermatologist for skin lesions. A dermatologist is an expert in the skin. BPDCN may be diagnosed through a lymph node or bone marrow biopsy.

A BPDCN diagnosis requires at least 4 of the following 6 proteins:

- CD123
- CD4
- CD56
- TCL-1
- CD2AP
- CD303/BDCA-2 without myeloid, T lineage, or B lineage expression markers. Myeloid markers include: MPO, lysozyme, CD14, CD34, CD116, and CD163.

A protein called CD123 is found at higher than normal levels on cancer cells in those with BPDCN. Biomarker and genetic testing will be done to confirm BPDCN.

For possible tests and procedures, see Guide 8.

Treatment overview

BPDCN is a difficult disease to treat. However, there are treatment options. It is important to find a doctor and hospital that has experience treating BPDCN.

Treating BPDCN takes a team approach. Treatment decisions should involve a multidisciplinary team or a team of doctors from different fields of medicine, including a dermatologist.

Treatment for BPDCN includes tagraxofusp-erzs or high-dose chemotherapy followed by hematopoietic cell transplant (HCT). Not everyone can tolerate this approach. BPDCN usually returns soon after treatment.

Guide 8
Possible tests and procedures: BPDCN

Medical history and physical exam (H&P)

Complete blood count (CBC), platelets, differential, and comprehensive metabolic panel (CMP)

Analysis of skin lesions (your doctor should work with a dermatologist), blood, bone marrow, and lymph nodes

Bone marrow aspirate and biopsy with lymph node biopsy

Biomarker and genetic testing

PET/CT, if leukemia outside the blood and bone marrow (extramedullary) or in lymph nodes suspected

Lumbar puncture (LP)
Intensive therapy

The goal of intensive therapy is to put BPDCN into remission (to achieve a complete response). Intensive therapy is not for everyone. Treatment will be based on factors such as your overall health and your body’s ability to tolerate drug therapies that could be toxic. Your wishes are also important. Talk with your care team about what to expect from treatment and what you want from treatment.

Tagraxofusp-erzs (preferred)

Tagraxofusp-erzs (Elzonris) is a biologic therapy. A biologic is made from a living organism or its by-product like in a vaccine. It helps to improve the body’s natural response against cancer.

Tagraxofusp-erzs targets the CD123 protein marker found at higher levels on BDPCN cancer cells. This leads to cancer cell death. You must be in good overall health to receive this treatment. Tagraxofusp-erzs can cause harmful side effects.

The first cycle of this drug should be given in a hospital where it is recommended you stay for at least 24 hours after the treatment is complete. This is to monitor for toxicity and to treat side effects. You will probably spend more than one week in the hospital.

Chemotherapy

There are 3 chemotherapy induction options:

- Cytarabine with idarubicin or daunorubicin
- HyperCVAD
- CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)

In hyperCVAD chemotherapy, treatment alternates between two groups of drugs. Hyper means the chemotherapy is given in smaller doses and more often to minimize side effects. CVAD stands for the first group of drugs: cyclophosphamide, vincristine, doxorubicin (also known by its trade name, Adriamycin), and dexamethasone. The second group of drugs consists of methotrexate and cytarabine. Sometimes, other drugs are added.

Complete remission

After a complete response, options are to continue tagraxofusp-erzs until disease progression or consider a hematopoietic cell transplant (HCT). After an HCT, you will enter surveillance. Surveillance is a plan that closely watches your condition. You might hear it called watch-and-wait. During this time, you will have tests on a regular basis to look for changes in your blood. You will not have any treatment during surveillance.

Surveillance includes a complete blood count (CBC) every 1 to 3 months for 2 years, then every 3 to 6 months for up to 5 years. If results aren’t normal, you might have a bone marrow aspirate and biopsy. You might also have a PET/CT if you had extramedullary disease before. This is cancer that might be in the lymph nodes or other organs. Skin or other lesions might be biopsied.

Less than complete remission

If BPDCN does not seem to be responding to treatment or there is less than a complete response, then it will be treated as refractory disease. If the skin still shows microscopic disease (CRc), you might have more cycles (at least 4) of therapy before starting treatment for refractory disease.
No intensive therapy

If intensive therapy is not an option, then treatment options are based on whether BPDCN is systemic or localized. In both cases, treatment is to palliate or to give relief.

Localized disease

If BPDCN is found only in the skin or isolated to a certain area of the body, then treatment will focus on those areas. It might include radiation therapy to the lesion(s) or surgery to remove lesions.

Systemic disease

Systemic means the cancer is throughout the body. Treatment includes a venetoclax-based therapy, systemic steroids, and supportive care. Venetoclax-based therapy is a low-intensity targeted therapy.

Relapsed and refractory

When leukemia returns, it is called a relapse. The goal of treatment is to achieve remission again. You may receive treatment to prevent the blasts from spreading to your brain and spine. Relapse is common in BPDCN. Not everyone responds to treatment in the same way.

When leukemia does not respond to treatment or progresses despite treatment, it is called refractory or resistant cancer. The cancer may be resistant at the start of treatment or it may become resistant during treatment.

A clinical trial is the preferred treatment for relapsed and refractory BPDCN. Tagraxofusp-erzs (Elzonris) is also a preferred option, if it was not used before. Other options include systemic therapy or radiation. See Guide 9.

Guide 9

Treatment options: Relapsed and refractory BPDCN

- Evaluate central nervous system (CNS) for disease
- Clinical trial (preferred)
- Tagraxofusp-erzs (preferred if not used before) with supportive care
- Chemotherapy (if not already used)
- Local radiation to isolated areas or specific lesions
- Systemic steroids
- Venetoclax-based therapy
- Start a donor search at first relapse for those who are candidates for a hematopoietic cell transplant (HCT) with no sibling donor match
Supportive care

Supportive care is health care that relieves your symptoms caused by cancer and improves your quality of life. It is not cancer treatment. In BPDCN, supportive care might include radiation therapy or surgery to treat skin lesions. Everyone with BPDCN should have a dermatologist as part of their care team.

Dermatologist

It is important to see a dermatologist and that your doctors work together on your treatment.

Tagraxofusp-erzs

Tagraxofusp-erzs can have very serious side effects. You will have blood tests to closely monitor your health. Capillary leak syndrome and hypoalbuminemia are serious and life-threatening conditions that can occur if you take tagraxofusp-erzs.

Capillary leak syndrome

Tagraxofusp-erzs injection may cause a serious and life-threatening reaction called capillary leak syndrome. In capillary leak syndrome, fluid and proteins leak out of tiny blood vessels causing dangerously low blood pressure. This may lead to organ failure and death. You will be monitored for capillary leak syndrome. You might be asked to weigh yourself every day while taking tagraxofusp-erzs. Sudden weight gain might be a sign of capillary leak syndrome.

Hypoalbuminemia

Hypoalbuminemia is a medical sign that protein levels of albumin are too low in the blood. It is most often the result of capillary leak syndrome.

Key points

- Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive blood cancer of immature plasmacytoid dendritic cells, a type of immune cell.
- BPDCN affects the blood, bone marrow, and skin. It can also affect the lymph nodes, spleen, and central nervous system (CNS).
- BPDCN is often found through a skin biopsy after a visit to the dermatologist for skin lesions.
- BPDCN is treated with a biologic therapy called tagraxofusp-erzs or with a combination of chemotherapies. A hematopoietic cell transplant (HCT) might follow treatment.
- Capillary leak syndrome and hypoalbuminemia are serious and life-threatening conditions that can occur if you take tagraxofusp-erzs.
- A clinical trial is the preferred treatment for relapsed and refractory BPDCN.

Need help paying for medicine or treatment?

Ask your care team what options are available.
Making treatment decisions

62  It’s your choice
62  Questions to ask
72  Resources
It’s your choice

In shared decision-making, you and your care team share information, discuss the options, and agree on a treatment plan. It starts with an open and honest conversation between you and your care team.

Treatment decisions are very personal. What is important to you may not be important to someone else.

Some things that may play a role in your decision-making:

- What you want and how that might differ from what others want
- Your religious and spiritual beliefs
- Your feelings about certain treatments
- Your feelings about pain or side effects
- Cost of treatment, travel to treatment centers, and time away from school or work
- Quality of life and length of life
- How active you are and the activities that are important to you

Think about what you want from treatment. Discuss openly the risks and benefits of specific treatments and procedures. Weigh options and share concerns with your care team. If you take the time to build a relationship with your care team, it will help you feel supported when considering options and making treatment decisions.

Second opinion

It is normal to want to start treatment as soon as possible. While cancer can’t be ignored, there is time to have another doctor review your test results and suggest a treatment plan. This is called getting a second opinion, and it’s a normal part of cancer care. Even doctors get second opinions!

Things you can do to prepare:

- Check with your insurance company about its rules on second opinions. There may be out-of-pocket costs to see doctors who are not part of your insurance plan.
- Make plans to have copies of all your records sent to the doctor you will see for your second opinion.

Support groups

Many people diagnosed with cancer find support groups to be helpful. Support groups often include people at different stages of treatment. Some people may be newly diagnosed, while others may be finished with treatment. If your hospital or community doesn’t have support groups for people with cancer, check out the websites listed in this book.

Questions to ask

Possible questions to ask your doctors are listed on the following pages. Feel free to use these questions or come up with your own. Be clear about your goals for treatment and find out what to expect from treatment.
Questions about diagnosis and testing

1. What subtype of AML do I have? What does this mean in terms of my prognosis and treatment options?
2. What tests do I need? What other tests do you recommend?
3. How soon will I know the results and who will explain them to me?
4. Where will the tests take place? How long will the tests take?
5. Will treatment start before the test results are in?
6. Is there a cancer center or hospital nearby that specializes in my type and subtype of cancer?
7. What will you do to make me comfortable during testing?
8. Would you give me a copy of the pathology report and other test results?
9. Who will talk with me about the next steps? When?
10. How many bone marrow tests are needed? When are they done?
Questions about options

1. What will happen if I do nothing?
2. Am I a candidate for a hematopoietic cell transplant (HCT)?
3. Am I a candidate for a clinical trial?
4. Can I join a clinical trial at any time?
5. Which option is proven to work best for my cancer, age, health, and other factors?
6. Can I stop treatment at any time? What will happen if I stop treatment?
7. What are my options if treatment doesn’t work as expected?
8. How will I know when blood transfusions or antibiotics are needed?
9. What decisions must be made today? Is there a social worker or someone who can help me decide?
10. Is there a hospital or treatment center you can recommend for treatment?
Questions about treatment

1. Which treatment do you recommend and why?
2. Which treatment will give me the best quality of life?
3. Which treatment will extend life? By how long?
4. What should I expect from this treatment?
5. When will I start treatment?
6. How long will treatment take?
7. How much will my insurance pay for this treatment?
8. What are the chances my cancer will return?
9. How will my cancer be treated if it returns?
10. How long will treatment last?
Questions about your care team’s experience

1. What is your experience treating AML?
2. What is the experience of those on your team?
3. Do you only treat AML? What other types of cancer do you treat?
4. I would like another pathologist or hemopathologist to review my blood samples. Is there someone you recommend?
5. How many people like me (of the same age, gender, race) have you treated?
6. Will you be consulting with AML experts to discuss my health care? Whom will you consult?
7. How many procedures like the one you’re suggesting have you done?
8. Is this treatment a major part of your practice?
9. How many of your patients have had complications? What were the complications?
10. Who will manage my day-to-day care?
Questions about side effects

1. What are the side effects of this treatment?
2. How long will these side effects last?
3. Do any side effects lessen or worsen in severity over time?
4. What side effects are expected and which are life threatening?
5. When should I call the doctor? Can I text?
6. What should I do for an issue on weekends and other non-office hours?
7. What medicines can I take to prevent or relieve side effects?
8. Will you stop treatment or change treatment if there are side effects? What do you look for?
9. What can I do to lessen or prevent side effects? What will you do?
10. What side effects are life-long and irreversible even after completing treatment?
Questions about blood transfusions

1. How often will I need blood transfusions?
2. How long does a transfusion take?
3. How will I feel after a transfusion?
4. Can I be given blood donated by family members?
5. Should my friends and family donate blood?
6. What are the side effects of blood transfusions?
7. Can my body reject blood transfusions? Is this serious?
8. If my body rejects a blood transfusion, will I be able to have more blood transfusions?
Questions about radiation therapy

1. What type of radiation therapy (RT) will I have?
2. What will you target?
3. What is the goal of this RT?
4. How many treatment sessions will I require?
5. Can you do a shorter course of RT?
6. Do you offer this type of RT here? If not, should you refer me to someone who does?
7. What side effects can I expect from RT?
8. Should I eat or drink before RT?
9. Will I be given medicine to help me relax during RT?
10. What should I wear?
Questions about hematopoietic cell transplants

1. Which type of hematopoietic cell transplant (HCT) is an option for me?
2. How do you find a donor?
3. What are the risks to myself and/or the donor?
4. How will an HCT affect my prognosis?
5. How will an HCT affect the quality and length of my life?
6. How long should I expect to be in the hospital?
7. How will I feel before, during, and after the HCT?
8. How many HCTs has this center done for my type of AML?
9. Will I have more than one HCT?
10. What side effects may occur after an HCT?
Questions about clinical trials

1. What clinical trials are available?
2. What are the treatments used in the clinical trial?
3. What does the treatment do?
4. Has the treatment been used before? Has it been used for other types of cancer?
5. What are the risks and benefits of this treatment?
6. What side effects should I expect?
7. How will the side effects be controlled?
8. How long will I be in the clinical trial?
9. Will I be able to get other treatment if this doesn’t work?
10. Will the clinical trial cost me anything? If so, how much?
## Resources

Many of these resources are also available en español and other languages.

<table>
<thead>
<tr>
<th>Resource</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Cancer Society (ACS)</td>
<td>cancer.org/cancer/leukemia.html</td>
</tr>
<tr>
<td>Aplastic Anemia &amp; MDS International Foundation (AAMDSIF)</td>
<td>aamds.org</td>
</tr>
<tr>
<td>American Association for Cancer Research (AACR)</td>
<td>aacr.org</td>
</tr>
<tr>
<td>American Society of Clinical Oncology (ASCO)</td>
<td>cancer.net</td>
</tr>
<tr>
<td>American Society of Hematology</td>
<td>hematology.org/education/patients</td>
</tr>
<tr>
<td>Be The Match®</td>
<td>bethematch.org</td>
</tr>
<tr>
<td>Blood &amp; Marrow Transplant Information Network</td>
<td>bmtinfonet.org</td>
</tr>
<tr>
<td>CancerCare</td>
<td>cancercare.org</td>
</tr>
<tr>
<td>Cancer Hope Network</td>
<td>cancerhopenetwork.org</td>
</tr>
<tr>
<td>Cancer Support Community</td>
<td>cancersupportcommunity.org/living-cancer</td>
</tr>
<tr>
<td>Chemocare</td>
<td>chemocare.com</td>
</tr>
<tr>
<td>MedlinePlus</td>
<td>medlineplus.gov</td>
</tr>
<tr>
<td>National Bone Marrow Transplant Link (nbmtLINK)</td>
<td>nbmtlink.org</td>
</tr>
<tr>
<td>National Cancer Institute (NCI)</td>
<td>cancer.gov/types/leukemia</td>
</tr>
<tr>
<td>National Coalition for Cancer Survivorship (NCCS)</td>
<td>canceradvocacy.org/toolbox</td>
</tr>
<tr>
<td>National Hospice and Palliative Care Organization (NHPCO)</td>
<td>caringinfo.org</td>
</tr>
<tr>
<td>National Organization for Rare Disorders (NORD)</td>
<td>rarediseases.org</td>
</tr>
<tr>
<td>OncoLink</td>
<td>oncolink.org</td>
</tr>
<tr>
<td>Patient Access Network Foundation</td>
<td>panfoundation.org</td>
</tr>
<tr>
<td>Radiological Society of North America</td>
<td>radiologyinfo.org</td>
</tr>
<tr>
<td>Testing.com</td>
<td>testing.com/resources</td>
</tr>
<tr>
<td>The Leukemia &amp; Lymphoma Society</td>
<td>lls.org/leukemia/acute-myeloid-leukemia</td>
</tr>
</tbody>
</table>
Words to know

**acute myeloid leukemia (AML)**
A fast-growing cancer of young white blood cells called myeloblasts.

**acute promyelocytic leukemia (APL)**
A fast-growing subtype of AML.

**allogeneic**
Donor who may or may not be related to you.

**all-trans retinoic acid (ATRA)**
ATRA is made in the body from vitamin A. ATRA made in a lab is used to treat APL.

**anemia**
A health condition in which the number of red blood cells is low.

**antimetabolite**
A drug that interferes with normal cell division and cell function.

**arsenic trioxide (ATO)**
A drug used to treat APL that has a fusion gene PML::RARA.

**autologous**
Stem cells come from you.

**best supportive care**
Treatment to improve quality of life and relieve discomfort.

**biomarker testing**
A lab test of any molecule in your body that can be measured to assess your health. Also called molecular testing.

**blast**
An immature white blood cell. Also called a myeloblast.

**blastic plasmacytoid dendritic cell neoplasm (BPDCN)**
A rare, aggressive blood cancer that has features of leukemia, lymphoma, and skin cancer.

**blood stem cell**
A blood-forming cell from which all other types of blood cells are formed. Also called hematopoietic stem cell.

**bone marrow**
The sponge-like tissue in the center of most bones where blood cells are made.

**bone marrow aspirate**
The removal of a small amount of liquid bone marrow to test for a disease.

**bone marrow biopsy**
The removal of a small amount of solid bone and bone marrow to test for a disease.

**chemotherapy**
Drugs that kill fast-dividing cells, including cancer cells and normal cells.

**chromosome**
Long strands that contain bundles of coded instructions for making and controlling cells.

**complete response (CR)**
An absence of all signs and symptoms of cancer after treatment. Also called complete remission.

**computed tomography (CT)**
A test that uses x-rays from many angles to make a picture of the insides of the body.
**consolidation**
A shorter and more intense treatment phase to further reduce the number of cancer cells. It is the second phase of treatment.

**contrast**
A substance put into your body to make clearer pictures during imaging tests.

**core binding factor (CBF) AML**
A form of AML that creates a shortage of all types of mature blood cells.

**cytogenetic complete response**
The absence of t(15;17) after treatment for acute promyelocytic leukemia (APL).

**cytogenetics**
The study of chromosomes using a microscope.

**cytopenia**
A health condition when the number of blood cells is lower than normal.

**deoxyribonucleic acid (DNA)**
Long strands of genetic information found inside cells.

**differential**
A lab test of the number of white blood cells for each type.

**differentiation syndrome**
A group of health signs and symptoms that is caused by leukemia or its treatments.

**extramedullary**
Outside the bone marrow.

**flow cytometry**
A lab test of substances on the surface of cells to identify the type of cells present.

**fluorescence in situ hybridization (FISH)**
A lab test that uses special dyes to look for abnormal chromosomes and genes.

**fusion gene**
A gene that is made when parts of two separate genes join.

**gene**
A set of coded instructions in cells for making new cells and controlling how cells behave.

**graft-versus-host disease (GVHD)**
A disease that occurs when transplanted blood stem cells attack a patient's normal cells.

**hematologist**
A doctor who’s an expert in diseases of the blood.

**hematopathologist**
A doctor who specializes in the study of blood diseases and cancers using a microscope.

**hematopoietic cell**
An immature blood-forming cell from which all blood cells are formed. Also called blood stem cell.

**hematopoietic cell transplant (HCT)**
A treatment that replaces damaged or diseased cells in the bone marrow with healthy blood-forming cells. Also called stem cell transplant (SCT) or bone marrow transplant (BMT).

**hereditary**
Passed down from biological parent to child through coded information in cells (genes).

**human leukocyte antigen (HLA)**
Special proteins on the surface of cells that help the body to tell its own cells apart from foreign cells.

**immunohistochemistry (IHC)**
A lab test used to find specific cell traits.

**immunophenotyping**
A lab test that detects the type of cells present based on the cells’ surface proteins.
Words to know

induction
The first phase of treatment.

lumbar puncture (LP)
A procedure that removes spinal fluid with a needle. Also called a spinal tap.

magnetic resonance imaging (MRI)
A test that uses radio waves and powerful magnets to make pictures of the insides of the body.

maintenance
Usually the last treatment phase given to prolong treatment results.

medullary
In the bone marrow.

molecular complete response
The absence of the PML::RARA gene after treatment for acute promyelocytic leukemia (APL).

morphologic complete response
A large decrease in number or percent of blasts after treatment for acute leukemia.

mutation
An abnormal change.

myeloid
Referring to a type of white blood cell called a granulocyte.

myelosuppression
A condition in which bone marrow activity is decreased, resulting in fewer red blood cells, white blood cells, and platelets.

pathologist
A doctor who’s an expert in testing cells and tissue to find disease.

peripheral blood
Blood that circulates throughout the body.

platelet (PLT)
A type of blood cell that helps control bleeding. Also called thrombocyte.

polymerase chain reaction (PCR)
A lab process in which copies of a piece of DNA are made.

positron emission tomography (PET)
A test that uses radioactive material to see the shape and function of body parts.

prognosis
The likely course and outcome of a disease.

progression
The growth or spread of cancer during or after treatment.

recovery
A period of time without treatment to allow blood cell counts to return to normal.

red blood cell (RBC)
A type of blood cell that carries oxygen from the lungs to the rest of the body. Also called an erythrocyte.

refractory
A cancer that does not improve with treatment.

regimen
A treatment plan that includes specific information about drug dose, when medicine is taken, and how long treatment will last.

relapse
The return or worsening of cancer after a period of improvement.

remission
There are minor or no signs of a disease.

resistance
When cancer does not respond to a drug treatment.
**Words to know**

- **side effect**
  An unhealthy or unpleasant physical or emotional response to treatment.

- **standard of care**
  The best-known way to treat a particular disease based on past clinical trials. There may be more than one treatment regimen that is considered standard of care.

- **subtype**
  A smaller group within a type of cancer that is based on certain cell features.

- **supportive care**
  Health care that includes symptom relief but not cancer treatment. Also called palliative care or best supportive care.

- **surveillance**
  Testing that is done after treatment ends to check for the return of cancer.

- **systemic therapy**
  Treatment that works throughout the body.

- **targeted therapy**
  A drug treatment that targets and attacks specific cancer cells.

- **translocation**
  When pieces of two chromosomes (long strands of coded instructions for controlling cells) break off and switch with each other.

- **tumor lysis syndrome (TLS)**
  A condition caused when waste released by dead cells is not quickly cleared out of your body.

- **white blood cell (WBC)**
  A type of blood cell that helps fight infections in the body. Also called a leukocyte.
This patient guide is based on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia, Version 1.2023. It was adapted, reviewed, and published with help from the following people:

Dorothy A. Shead, MS  
Senior Director  
Patient Information Operations

Tanya Fischer, MEd, MSLIS  
Senior Medical Writer

Laura Phillips  
Graphic Design Artist

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia, Version 1.2023 were developed by the following NCCN Panel Members:

*Daniel A. Pollyea, MD, MS/Chair  
University of Colorado Cancer Center

Jessica K. Altman, MD/Vice Chair  
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Dale Bixby, MD, PhD  
University of Michigan  
Rogel Cancer Center

*Amir T. Fathi, MD  
Massachusetts General Hospital  
Cancer Center

James M. Foran, MD  
Mayo Clinic Comprehensive Cancer Center

Ivana Gojo, MD  
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Aric C. Hall, MD  
University of Wisconsin  
Carbone Cancer Center

Brian Jonas, MD  
UC Davis Comprehensive Cancer Center

Ashwin Kishtagari, MD  
Vanderbilt-Ingram Cancer Center

Jeffrey Lancet, MD  
Moffitt Cancer Center

Lori Maness, MD  
Fred & Pamela Buffett Cancer Center

James Mangan, MD  
UC San Diego Moores Cancer Center

Gabriel Mannis, MD  
Stanford Cancer Institute

Guido Marcucci, MD  
City of Hope National Medical Center

Alice Mims, MD, MS  
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Kelsey Moriarty, MS,CGC  
UT Southwestern Simmons Comprehensive Cancer Center

Moaath Mustafa Ali, MD, MPH  
Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute

Jadee Neff, MD, PhD  
Duke Cancer Institute

Reza Nejati, MD  
Fox Chase Cancer Center

Rebecca Olin, MD, MS  
UCSF Helen Diller Family Comprehensive Cancer Center

Mary-Elizabeth Percival, MD, MS  
Fred Hutchinson Cancer Center

Alexander Perl, MD  
Abramson Cancer Center at the University of Pennsylvania

*Amanda Przesopleski, DO  
Roswell Park Comprehensive Cancer Center

Dinesh Rao, MD, PhD  
UCLA Jonsson Comprehensive Cancer Center

Farhad Ravandi, MD  
The University of Texas  
MD Anderson Cancer Center

Rory Shallis, MD  
Yale Cancer Center/Smilow Cancer Hospital

Paul J. Shami, MD  
Huntsman Cancer Institute at the University of Utah

Eytan Stein, MD  
Memorial Sloan Kettering Cancer Center

Richard M. Stone, MD  
Dana-Farber/Brigham and Women’s Cancer Center

Stephen A. Strickland, MD, MSCI  
Vanderbilt-Ingram Cancer Center

Kendra Sweet, MD, MS  
Moffitt Cancer Center

Swapna Thota, MD  
St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center

Geoffrey Uy, MD  
Siteman Cancer Center at Barnes-JewishHospital and Washington University School of Medicine

Pankit Vachhani, MD  
O’Neal Comprehensive Cancer Center at UAB

* Reviewed this patient guide. For disclosures, visit NCCN.org/disclosures.
NCCN Cancer Centers

Abramson Cancer Center at the University of Pennsylvania
Philadelphia, Pennsylvania
800.789.7366 • pennmedicine.org/cancer

Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio
800.641.2422 • UH Seidman Cancer Center uhhospitals.org/services/cancer-services
866.223.8100 • CC Taussig Cancer Institute my.clevelandclinic.org/departments/cancer
216.844.8797 • Case CCC case.edu/cancer

City of Hope National Medical Center
Duarte, California
800.826.4673 • cityofhope.org

Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center
Boston, Massachusetts
617.732.5500 • youhaveus.org
617.726.5130 massgeneral.org/cancer-center

Duke Cancer Institute
Durham, North Carolina
888.273.3853 • dukecancerinstitute.org

Fox Chase Cancer Center
Philadelphia, Pennsylvania
888.369.2427 • foxchase.org

Fred & Pamela Buffett Cancer Center
Omaha, Nebraska
402.559.5600 • unmc.edu/cancercenter

Fred Hutchinson Cancer Center
Seattle, Washington
206.667.5000 • fredhutch.org

Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah
800.824.2073 • huntsmancancer.org

Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana
888.600.4822 • www.cancer.iu.edu

Mayo Clinic Comprehensive Cancer Center
Phoenix/Scottsdale, Arizona
Jacksonville, Florida
Rochester, Minnesota
480.301.8000 • Arizona
904.953.0853 • Florida
507.538.3270 • Minnesota
mayoclinic.org/cancercenter

Memorial Sloan Kettering Cancer Center
New York, New York
800.525.2225 • mskcc.org

Moffitt Cancer Center
Tampa, Florida
888.663.3488 • moffitt.org

O’Neal Comprehensive Cancer Center at UAB
Birmingham, Alabama
800.822.0933 • uab.edu/onealcancercenter

Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois
866.587.4322 • cancer.northwestern.edu

Roswell Park Comprehensive Cancer Center
Buffalo, New York
877.275.7724 • roswellpark.org

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
St. Louis, Missouri
800.600.3606 • siteman.wustl.edu

St. Jude Children’s Research Hospital/ The University of Tennessee Health Science Center
Memphis, Tennessee
866.278.5833 • stjude.org
901.448.5500 • uthsc.edu

Stanford Cancer Institute
Stanford, California
877.668.7535 • cancer.stanford.edu

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
410.955.8964 • hopkinskimmelcancercenter.org

The University of Texas MD Anderson Cancer Center
Houston, Texas
844.269.9222 • mdanderson.org

UC Davis Comprehensive Cancer Center
Sacramento, California
916.734.5959 • 800.770.9261
health.ucdavis.edu/cancer

UC San Diego Moores Cancer Center
La Jolla, California
858.822.6100 • cancer.ucsd.edu

UCLA Jonsson Comprehensive Cancer Center
Los Angeles, California
310.825.5268 • cancer.ucla.edu

UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California
800.689.8273 • cancer.ucsf.edu

University of Colorado Cancer Center
Aurora, Colorado
720.848.0300 • coloradocancercenter.org

University of Michigan Rogel Cancer Center
Ann Arbor, Michigan
800.865.1125 • rogelcancercenter.org

University of Wisconsin Carbone Cancer Center
Madison, Wisconsin
608.265.1700 • uwhealth.org/cancer

UT Southwestern Simmons Comprehensive Cancer Center
Dallas, Texas
214.648.3111 • utsouthwestern.edu/simmons

Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
877.936.8422 • vicc.org

Yale Cancer Center/Smilow Cancer Hospital
New Haven, Connecticut
855.4.SMILOW • yalecancercenter.org

NCCN Guidelines for Patients®
Acute Myeloid Leukemia, 2023
Index

acute promyelocytic leukemia (APL) 48–54
all-trans retinoic acid (ATRA) 49, 51
biomarker testing 16–18
blastic plasmacytoid dendritic cell neoplasm (BPDCN) 55–60
blasts 7
blood clotting tests 11
bone marrow aspirate and biopsy 14–15
blood transfusions 44–45
bloodless or blood-free transfusions 44–45
chemotherapy 25–26
clinical trials 28–29
complete response (CR) or remission 36, 50, 58
consolidation 37, 42, 50
differentiation syndrome 46, 54
echocardiogram 19
electrocardiogram (ECG) 19
 genetic testing 16–18
graft-versus-host disease (GVHD) 30
growth factors 46
hematopoietic cell transplant (HCT) 30
human leukocyte antigen (HLA) typing 13
hydroxyurea 44, 46
hypomethylating agents (HMLAs) 26
induction 37, 39–41, 50
low ejection fraction 19, 52
lumbar puncture (LP) 20
magnetic resonance imaging (MRI) 18
maintenance 37, 42, 50, 52
minimal or measurable residual disease (MRD) 37
monitoring 37, 42, 52
multigated acquisition (MUGA) scan 19
mutations 16, 27, 40–43
performance status 14
polymerase chain reaction (PCR) 17
prolonged QTc 19, 52
radiation therapy 31
refractory disease 43, 59
relapsed disease 43, 53, 59
response types 36, 50, 58
risk groups 38–41
steroids 31
supportive care 31–33, 54, 60
surveillance 37, 42, 52
tagraxofusp-erzs 58
targeted therapy 27
transfusions 44–45
tumor lysis syndrome (TLS) 46
Acute Myeloid Leukemia

2023

To support the NCCN Guidelines for Patients, visit

NCCNFoundation.org/Donate